

- 1 -

VIRAL VECTORS EXPRESSING FUSION OF VIRAL LARGE ENVELOPE PROTEIN AND PROTEIN OF INTEREST**BACKGROUND OF THE INVENTION****FIELD OF THE INVENTION**

The present invention relates generally to virus-like particles (VLPs) for use in delivering a polypeptide of interest to a subject and to nucleic acid molecules encoding same. In particular, the present invention takes advantage of features of avian hepadnavirus particles to generate stable recombinant VLPs which are useful in the delivery to a subject of a polypeptide of interest. The polypeptide of interest may comprise one or more antigens capable of eliciting an immune response. The VLPs comprising the polypeptide of interest are useful for delivery of an antigen to the immune system of a subject or in the presentation of epitopes for the detection of antibodies in *in vitro* assays. The present invention extends, *inter alia*, to plasmids, cells, kits and methods which are useful in the generation, production, delivery and monitoring of the instant VLPs.

DESCRIPTION OF THE PRIOR ART

Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

Reference herein to prior art, including any one or more prior art documents, is not to be taken as an acknowledgment, or suggestion, that said prior art is part of the state of the art.

The hepadnaviruses are a family of enveloped DNA viruses. Assembly of mammalian hepadnaviruses, such as hepatitis B virus, is complex and mature virions are formed by the interaction of preformed cytoplasmic core particles with pre-assembled surface proteins on the host endoplasmic reticulum (ER) membrane. Following interaction with appropriate portions of envelope proteins, the nucleocapsids bud into the lumen of the ER along with a 1000-fold excess of empty, subviral particles (SVPs) and assembly is completed in an

- 2 -

intermediate, pre-Golgi compartment (as reviewed by Nassal, M., *Curr. Top. Microbiol. Immunol.*, 214:297-337, 1996).

In many studies, virus-like particles (VLPs), which lack nucleocapsids, have proven to be promising candidate vaccines since they: (i) are non-infectious and therefore safe to produce and use, (ii) are more immunogenic than subunit vaccines because they provide the necessary spatial structure for display of epitopes, and (iii) elicit humoral, cell-mediated and importantly, mucosal immunity (Krueger, *et al.*, *Biol. Chem.* 380:275-276, 1999).

A recent example of a successful VLP vaccine, currently in clinical trials, is the recombinant papillomavirus major capsid protein (L1) VLP, which prevents infection by inducing a strong neutralizing antibody response (Frazer, *Virus Research*, 89:271-274, 2002).

The hepatitis B virus (HBV) subviral particle (HBsAg-S) has been viewed as a candidate to produce recombinant VLPs. Several studies have examined which domains are suitable for insertion of foreign epitopes (Bruss *et al.*, *EMBO J.*, 13:2273-2279, 1994., 1994; Delpeyroux *et al.*, *J. Mol. Biol.* 195:343-350, 1987), including N terminal fusion of the preS domain (Prange, *et al.*, *J. Gen. Virol.* 76:2131-2140, 1995).

Most recently, particles carrying small, 35 amino acid insertions of the hepatitis C virus (HCV) hypervariable region 1 of the E2 envelope protein into the exposed 'a' determinant in the second hydrophilic loop have successfully elicited antibody responses (Netter, *et al.*, *J. Virol.* 75:2130-2141, 2001). Notably, there have been limitations to the size of the inserts tolerated for particle stability and a loss of immune reactivity to the 'a' determinant of HBsAg when particles were produced in a mammalian cell system (Prange *et al.*, 1995, *supra*; Bruss *et al.*, *J. Virol.* 65:3813-3820, 1991).

- 3 -

Particle instability with large fusions has recently been overcome with a Dengue virus/HBsAg fusion by expression in yeast (Bisht, *et al*, *J. Biotechnology*. 99:97-110, 2002).

However, in all these cases, in order to assemble chimeric particles, the recombinant S protein must assemble with wild type S subunits. These extended S chains present a difficulty for inclusion in the tight envelope lattice formed by the HBsAg (which excludes L) and so their number is limited, and consequently the immune response generated to the foreign epitopes is low.

Accordingly, there is a need for improved VLPs which efficiently incorporate polypeptides of interest.

SUMMARY OF THE INVENTION

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Nucleotide and amino acid sequences are referred to by sequence identifier numbers (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1, <400>2, etc. A summary of sequence identifiers is provided in Table 1. A sequence listing is provided after the claims.

The envelope protein of duck hepatitis B virus (DHBV) and other avian hepadnaviruses consists of two proteins, the large envelope protein (L) and the small envelope protein (S), which are produced by differential in-frame translation initiation from a single preS/S open reading frame. L and S polypeptides have a common C terminal membrane spanning or S domain, while L has an approximately 160 amino acid N-terminal extension (or preS domain) encompassing a receptor binding region. The S polypeptide is the major viral envelope constituent, which determines envelope curvature and can drive particle secretion even in the absence of the nucleocapsid. In contrast L polypeptide can only be exported when co-assembled with S.

The assembly of DHBV envelope proteins and their involvement in host cell entry are closely linked to a unique topological switch adopted by hepadnaviruses, in which a large N-terminal preS domain of the L protein is post-translocationally translocated across the ER membrane. This process is regulated so that generally only approximately 50% of molecules have translocated N-termini and the mature particle contains mixed internal/external topologies, including a partially translocated or intermediate form.

The present invention is predicted, in part, on the surprising discovery that substantial regions of L polypeptide of DHBV are dispensable for L translocation and particle

- 5 -

assembly, including regions in the S domain which have the same amino acid sequence as S polypeptide regions essential for particle assembly. Accordingly, L polypeptides are more flexible in their particle association than S polypeptides and thus open to more extensive manipulation.

The present invention, therefore, provides virus-like particles (VLPs) which primarily contain a small envelope (S) polypeptide or a functional derivative or homolog thereof. In addition, and in accordance with the present invention however, they comprise a fusion polypeptide comprising a polypeptide of interest (POI) and at least a particle associating portion of a large envelope (L) polypeptide or a functional derivative or homolog thereof. Because the L polypeptide is not excluded during VLP assembly and because it can be extensively manipulated to vector a heterologous polypeptide without significantly affecting particle stability, the VLP of the present invention will be useful, *inter alia*, in the delivery of a polypeptide of interest to a subject. In addition, because epitopes of an antigenic POI will be effectively displayed in a VLP, the VLPs are useful in assays for the detection of antibodies.

The present invention is described with particular reference to DHBV, however, the invention extends to L and S polypeptides from other viruses with L and S envelope polypeptides proteins in which L is not excluded from particle assembly. For example, L and S polypeptides from other avian hepadnaviruses are contemplated such as, but not limited to such heron (HHBV), snow goose (SGHBV) and hepadnaviruses which exhibit similar subviral particle morphology to DHBV, i.e., with L and S envelope proteins. The S domains of L and S polypeptides are highly conserved within all hepadnaviruses, exhibiting for example up to 70% amino acid similarity in the region between TM1 and TM2.

The present invention provides a virus-like particle (VLP) comprising i) a polypeptide comprising a polypeptide of interest (POI) and at least a particle associating portion of a large envelope (L) polypeptide of an avian hepadnavirus or a functional derivative or

- 6 -

homolog thereof, and ii) a small envelope (S) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof.

The present invention furthermore provides, a virus-like particle (VLP) comprising i) a fusion polypeptide comprising a polypeptide of interest (POI) and at least a particle associating portion of a large envelope (L) polypeptide of DHBV or a functional derivative or homolog thereof, and ii) a small envelope (S) polypeptide of DHBV or a functional derivative or homolog thereof.

By introducing one or more POIs into the L polypeptide, the POI is translocated along with L into a particle structure made up primarily of S polypeptide.

Although several examples of particle associating portions of the L polypeptide are provided, based on the teaching provided herein it would be well within the skill of the addressee to generate smaller or larger portions of L-polypeptide and determine whether they, together with a heterologous (or indigenous) protein of interest, are capable of particle association within a VLP. Accordingly, the present invention is in no way limited to the exemplified constructs.

The virus-like particles of the present invention are useful in vaccine compositions to promote an effective immune response. In particular embodiments, the virus-like particles are advantageously a suitable size to be taken up by antigen presenting cells, such as dendritic cells. For example, DHBV VLPs are significantly larger than mammalian HBV VLPs.

Recombinant VLPs of the present invention are prepared using expression plasmids comprising nucleic acid molecules encoding the recombinant L polypeptides separately or together with S polypeptides. Expression plasmids are conveniently in a form suitable for expression in yeast, baculovirus or avian or mammalian expression systems. Plasmids comprising nucleic acid molecules encoding the instant recombinant L polypeptides may also be used to deliver nucleic acid constructs directly to the cells of a subject.

- 7 -

Alternatively, kits are contemplated to facilitate recombinant production of the instant fusion proteins.

The present invention furthermore provides methods for producing a recombinant virus-like particle and compositions comprising a virus-like particle derived from L and S polypeptide of avian hepadnaviruses or other non-L excluding viruses for use as a vaccine or source of antigen wherein the L polypeptide comprises one or more antigens of interest derived from one or more heterologous sources.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of a cloning strategy for generating pCDL-E2.465

Figure 2A is a schematic representation of the large (L) and small (S) envelope proteins of DHBV. L and S are produced by differential translation from a single open reading frame such that L protein consists of a preS domain of 161 amino acids and a C-terminal S domain of 167 amino acids, which comprises the S protein. The three transmembrane domains (TM) are indicated by the boxes.

Figure 2B is a schematic representation of L showing where the 82 amino acid portion of the HCV E2 ectodomain (from aa 384 to 465) was inserted into the preS domain, generating the E2.465/L chimeric envelope protein.

Figure 2C provides the results of a Western Blot showing that the E2.465/L chimera is translocated across the ER. Protease protection analysis of ER microsomes prepared from LMH cells transfected with pCDL-E2.465 and pCI-S (an S protein expression plasmid). Microsomes samples were subjected to digestion with trypsin in the absence or presence of the detergent, NP-40, or left untreated, as denoted above each lane. Protease protection of E2.465/L chains was analysed by SDS-PAGE and Western blotting with a monoclonal anti-S antibody, which detects both E2.465/L and S proteins. Protection of E2.465/L from trypsin digestion (middle lane) is an indication of translocation to the ER lumen.

Figure 2D provides the results of a Western Blot showing that the E2.465/L chimera is assembled into particles. Intracellular particles were isolated from avian hepatoma (LMH) cells transfected with pCDL-E2.465 and pCI-S by freeze-thawing cells 3 times, centrifugation to obtain the cytosolic fraction for sedimentation of particles through 20% sucrose on to a 70% sucrose cushion at 38,000 r.p.m. (SW41 rotor Beckman). The particle fraction at the 20-70% sucrose interface was methanol precipitated prior to SDS-PAGE and analysis of envelope proteins by Western blotting.

- 9 -

Figure 2E is a schematic representation modelling the membrane orientations of L protein on the ER (depicted as microsome vesicles), showing the process of post-translational translocation to the microsome lumen, which confers protection from trypsin digestion of the E2.465/L hybrid chains. During particle assembly assembled envelope proteins bud from the ER into the ER lumen taking the inner leaflet of the ER membrane. Particles are exported from the cell via the cellular vesicular export pathway enabling isolation of particles both from the cytosolic (as shown in D) and extracellular compartments. Envelope protein domains translocated to the ER lumen are thus ultimately exposed to the outside of the assembled particle; as indicated by the schematic diagram of a particle.

Figure 3 is a representation showing the genomic nucleotide sequence of DHBV.

Figure 4 is a representation showing provides the amino acid sequences of L and S polypeptides of DHBV. Start sites are underlined and stop sites are starred (*).

Figure 5A is a schematic representation of DHBV L and DHBV S protein.

Figure 5B to 5H is a schematic representation of DHBV L chimeras. Boxes labelled TM1-3 represent the transmembrane domains. Numbers along the length of the DHBV L represent amino acid positions relative to the DHBV L sequence. The V indicates a deletion in TM1.

Figure 6A and 6B is a schematic representation showing results of Western blots of a membrane fraction of LMH cells transfected with pSigL Δ TM1-E2.661 (A) or pCDL Δ TM1-MSP2 (B). MW markers (40-120 kDa) are included to indicate the size of the chimeric L proteins.

Figure 7A and 7B is a schematic representation showing a Western blot of fractions from a sucrose step gradient showing that DI/S (A) and chimeric L VLPs, DL Δ TM1-E2.465/S (B) and DL Δ TM1-HpreS (C) produced in yeast have the same particle density. VLPs produced in yeast sedimented through 20% sucrose on to a 70% cushion were further

- 10 -

sedimented on a 20-70% sucrose step gradient for 5 hours at 38,000 rpm. Fractions collected from the gradient (no.s 2-11) were run on an SDS-PAGE and Western blotted with a monoclonal against the DHBV S domain.

Figure 8 is a schematic representation showing a Western blot of DHBV L protein probed with the sequential bleeds of one rat immunised with DL/S VLPs produced in yeast. Pre refers to the bleed taken before immunisation and nos 1-5 represent rat sera obtained at 3,6,9 and 13 weeks.

- 11 -

TABLE 1

SEQ ID NO.	SEQUENCE
SEQ ID NO: 1	Primers for generating L-fusion proteins
SEQ ID NO: 2	Primers for generating L-fusion proteins
SEQ ID NO: 3	Primers for generating L-fusion proteins
SEQ ID NO: 4	Primers for generating L-fusion proteins
SEQ ID NO: 5	Full genomic nucleotide sequence of DHBV
SEQ ID NO: 6	Nucleotide sequence encoding L polypeptide of DHBV
SEQ ID NO: 7	Amino acid sequence of L polypeptide of DHBV
SEQ ID NO: 8	Nucleotide sequence encoding S domain of L polypeptide of DHBV
SEQ ID NO: 9	Amino acid sequence of S domain of L polypeptide of DHBV
SEQ ID NO: 10	Nucleotide sequence encoding preS domain of L polypeptide of DHBV
SEQ ID NO: 11	Amino acid sequence of pre S domain of L polypeptide of DHBV
SEQ ID NO: 12	Nucleotide sequence encoding S polypeptide of DHBV
SEQ ID NO: 13	Amino acid sequence of S polypeptide of DHBV

- 12 -

DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated in part on the finding that L polypeptide of DHBV can be substantially modified yet still retain the ability to associate with S polypeptides of DHBV during virus-like particle assembly.

It is proposed herein to use an L polypeptide or a functional derivative or homolog thereof to deliver a polypeptide or peptide of interest to a subject. In particular, it is proposed to use an L polypeptide to deliver antigens of interest to the immune system of a subject as part of a virus-like particle.

In a broad embodiment the present invention provides a virus-like particle (VLP) comprising a fusion (chimeric) polypeptide comprising a polypeptide of interest (POI) and a particle associating portion of a large envelope (L) polypeptide.

The virus-like particle is primarily composed of a small envelope (S) polypeptide.

Accordingly, the present invention furthermore provides a VLP comprising i) fusion polypeptide comprising a polypeptide of interest (POI) and at least a particle associating portion of a large envelope (L) polypeptide or a functional derivative or homolog thereof, and ii) a small envelope (S) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof.

More specifically, the present invention furthermore provides a VLP comprising i) a fusion polypeptide comprising a polypeptide of interest (POI) and at least a particle associating portion of a large envelope (L) polypeptide of DHBV or a functional derivative or homolog thereof, and ii) a small envelope (S) polypeptide of DHBV or a functional derivative or homolog thereof.

Preferably at least part of said POI is exposed on the surface of the virus-like particle.

- 13 -

The term "virus-like particle" is used in its broadest sense to mean a particle or three dimensional proteinaceous structure which, like sub-viral particles of enveloped viruses, form particles by self-assembly or folding of envelope polypeptides within a lipid bilayer. The virus-like particles of the present invention may be recombinant or synthetic or may comprise a combination of synthetic and recombinant components.

Reference herein to the singular form such as "a", "an" or "the" includes the plural aspect unless the context clearly specifies otherwise. Thus, reference for example to "a polypeptide of interest" includes a single polypeptide, as well as two or more such polypeptides.

Reference herein to the term "polypeptide" means a polymer of amino acids and should not be limited to any particular length. Therefore, the term includes proteins, oligopeptides, peptides and epitopes. The term does not exclude modifications of the polypeptide, for example myristylation, glycosylation, phosphorylation, addition of N-terminal signal sequences and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including for example, unnatural amino acids such as those give in Table 2) or polypeptides with substituted linkages.

Analogous contemplated herein include but are not limited to modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogs.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

- 14 -

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH, palmitylation of cysteine residues.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 2.

TABLE 2
Codes for non-conventional amino acids

Non-conventional amino acid	Code	Non-conventional amino acid	Code
α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine	Nmasn
aminoisobutyric acid	Aib	L-N-methylaspartic acid	Nmasp
aminonorbornyl-carboxylate	Norb	L-N-methylcysteine	Nmcys
cyclohexylalanine	Chexa	L-N-methylglutamine	Nmgln
cyclopentylalanine	Cpen	L-N-methylglutamic acid	Nmglu
D-alanine	Dal	L-N-methylhistidine	Nmhis
D-arginine	Darg	L-N-methylisoleucine	Nmile
D-aspartic acid	Das	L-N-methylleucine	Nmleu
D-cysteine	Dcys	L-N-methyllysine	Nmlys
D-glutamine	Dgln	L-N-methylmethionine	Nmmet
D-glutamic acid	Dglu	L-N-methylnorleucine	Nmnle
D-histidine	Dhis	L-N-methylnorvaline	Nmnva
D-isoleucine	Dile	L-N-methylornithine	Nmorn
D-leucine	Dleu	L-N-methylphenylalanine	Nmphe
D-lysine	Dlys	L-N-methylproline	Nmpro
D-methionine	Dmet	L-N-methylserine	Nmser
D-ornithine	Dorn	L-N-methylthreonine	Nmthr
D-phenylalanine	Dphe	L-N-methyltryptophan	Nmtrp
D-proline	Dpro	L-N-methyltyrosine	Nmtyr
D-serine	Dser	L-N-methylvaline	Nmval
		L-N-methylethylglycine	Nmetg
		L-N-methyl-t-butylglycine	Nmtbug

- 16 -

D-threonine	Dthr	L-norleucine	Nle
D-tryptophan	Dtrp	L-norvaline	Nva
D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr

- 17 -

D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dmmet
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyl- <i>n</i> -naphthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L- α -methylalanine	Mala
L- α -methylarginine	Marg	L- α -methylasparagine	Masn
L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
L- α -methylserine	Mser	L- α -methylthreonine	Mthr
L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhph

- 18 -

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine	carbamylmethyl)glycine		
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(CH_2)_n$ spacer groups with $n=1$ to $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α -methylamino acids and the introduction of double bonds between C_α and C_β atoms of amino acids.

The terms "fusion polypeptide" or "chimeric polypeptide" or "hybrid polypeptide" are interchangeably used to mean a polypeptide, protein or peptide comprising two or more associated polypeptides which are expressed as part of the same expression product, or which are generated by synthetic means. Fusion polypeptides may comprise two or more L and POI polypeptides and intervening regions such as, for example, linker or spacer regions. In particular, regions which permit or directly or indirectly facilitate a surface topology or increase protease resistance for the polypeptide of interest in the particle are contemplated, for example, N-terminal signal sequences. An example of a signal sequence is preprolactin however there are many other suitable signal sequences, as will be understood by one of skill in the art. An example of a spacer region is a transmembrane domain. Alternatively, or in addition, regions which promote a cytosolic topology may be included. Polypeptide topology in a viral particle may be assessed for example by protease protection assay or by determining interactivity with antibodies determined by the L polypeptide, S polypeptide, the polypeptide of interest or epitopes generated through fusion of these polypeptides. According, the term "fusion" in "fusion polypeptide" is not used in the sense of "viral fusion".

- 19 -

The term "polypeptide of interest" means any polypeptide which is advantageously delivered to a subject as part of a virus-like particle. For example, two or more or a matrix of polypeptides involved in promoting and/or mediating a particular biochemical or physiological reaction may be delivered to a subject in viral particle form. A particular reaction contemplated is an immune response to an antigen. Accordingly the term includes any antigenic polypeptide of interest. Antigenic polypeptides may be co-expressed with immunopotentiating polypeptides such as cytokines as is well known in the art. The polypeptides and peptides of the present invention (POIs) may furthermore be expressed or synthesised in L with molecules which serve as targeting and/or marker molecules such as, without limitation, molecules which assist in targeting and/or marking particular cells, such as dendritic or other antigen presenting cells.

"Subject" as used herein refers to an animal, preferably a mammal and more preferably human who can benefit from administration of the viral particles of the present invention. There is no limitation on the type of animal that could benefit from the presently described molecules. A patient regardless of whether a human or non-human animal may be referred to as an individual, subject, animal, host or recipient. The molecules and methods of the present invention have applications in human medicine, veterinary medicine as well as in general, domestic or wild animal husbandry. For convenience, an "animal" includes an avian species such as a poultry bird, an aviary bird or game bird.

The preferred animals are humans or other primates, livestock animals, laboratory test animals, companion animals or captive wild animals.

Examples of laboratory test animals include ducks, snow geese, mice, rats, rabbits, guinea pigs and hamsters. Rabbits and rodent animals, such as rats and mice, provide a convenient test system or animal model. Livestock animals include sheep, cows, pigs, goats, horses and donkeys. Non-mammalian animals such as avian species, zebrafish and amphibians are also contemplated.

- 20 -

The terms "antigen" or "antigenic polypeptide" are used in their broadest sense to include polypeptides which are capable of inducing an immune response in a subject. The antigenic polypeptide may comprise single epitope regions through to multiple epitope regions including repeated epitope regions. The antigenic polypeptide may derive from a single or multiple sources although antigens from infectious agents, such as, for example, viruses, bacteria, fungi, protozoa, trematodes, nematodes, prions and the like are contemplated, as are tumour-related antigens. Antigenic regions of many agents and tumour-related proteins are well known in the art. Antigens are, for example, those from parasites, bacteria, viruses, cancers and those described herein include antigens from E2 polypeptide of Hepatitis, MSP2 polypeptide from *P. falciparum* and H protein from measles.

As is well known to those skilled in the art, effective immune responses for prophylactic or therapeutic vaccines generally elicit strong CTL and T-helper cell responses as well as strong humoral responses.

The antigenic polypeptide of interest may comprise epitope regions from two or more polypeptides from different organisms, species or subspecies. For example, viral and bacterial or multiple viral or multiple bacterial infectious may be vaccinated for simultaneously.

The phrase "particle associating portion" means for all L polypeptides, that or those portions of the L polypeptide which is/are required for L polypeptide incorporation into virus-like particles. For example, the TM1 region of the S domain of L is not required for L association with the particle and may be omitted from the L-polypeptide used herein. Indeed, as contemplated herein, the sequences downstream of TM1 (or downstream of TM2 and the 5' cysteine loop) of L polypeptide are sufficient for particle association. Similarly, the preS domain of L is not required for assembly of L in the particles. The S domain of L absent TM1 is an example of a particle associating portion of L. Many different particle association portions are clearly available pursuant to the present

- 21 -

invention. The nature of this portion is flexible and may be determined empirically using methods known in the art and referred to herein.

Although a minimum functional portion of L may be advantageous in some applications, the present invention extends full length L polypeptides interspersed with a POI or wherein the POI is terminally appended. Preferably the POI is introduced into surface exposed portions of L.

The term "derived from" means that a particular element or group of elements has originated from the source described, but has not necessarily been obtained directly from the specified source.

The term "isolated" includes reference to VLPs having undergone at least one purification step, conveniently described in terms of the % of pure material in a sample. Preferred forms include material which is at least 50% pure, more preferably at least 60%, more preferably at least 70%, more preferably at least about 80%, still more preferably at least about 90% pure VLP material in a sample.

One of the advantages of the present invention is that VLPs may be produced of generally consistent size.

In another aspect of the present invention an isolated virus-like particle (VLP) is contemplated comprising i) a fusion polypeptide comprising a polypeptide of interest (POI) and at least a portion of the S domain of a large envelope (L) polypeptide of an avian hepadnavirus such as DHBV or a functional derivative or homolog thereof; and ii) a small envelope (S) polypeptide of an avian hepadnavirus such as DHBV or a functional derivative or homolog thereof, wherein at least a part of said POI is exposed on the surface of the virus-like particle.

Signal sequences may conveniently be employed in order to effect expression of particular POI/L polypeptides in some expression systems, as required. As described herein, the

- 22 -

presence of a strong signal sequence is also used to enhance the amount of POI expressed on the surface of the VLP.

Exemplary portions of L are amino acids 24 to 167 of DHBV S domain or, more preferably at least TM2 (including the 5' cysteine loop between TM1 and TM2) and downstream sequences of L polypeptide of DHBV.

In one particular embodiment of the present invention, the polypeptide of interest is located at the amino terminal side of the S domain amino acid sequence of the L polypeptide or the S domain minus the TM1 domain. In another embodiment, the POI is located in the pre-S domain of the L polypeptide or N terminally to the L polypeptide.

By introducing one or more POIs into the pre-S domain of L or N terminally to the S domain of L or N-terminally to the S domain absent TM1, the POI is translocated along with L into a particle structure made up primarily of S polypeptide. This facilitates a high copy number of POI per VLP.

In one embodiment the virus-like particles of the present invention are useful in vaccine compositions to promote an effective immune response. In particular, the virus like particles are advantageously a suitable size to be taken up by antigen presenting cells, such as dendritic cells. Specifically, in relation to mammalian hepadnavirus particles, these are typically approximately 20 nanometers, while those of avian hepadnaviruses are pleomorphic and are typically between 35 and 60 nanometers in diameter. An effective immune response is one which is capable of reducing the number of target antigens in a subject and may prevent infections or development of disease conditions (prophylactic vaccine) or may treat current infections or conditions (therapeutic vaccination).

Without being bound to any particular theory, the VLPs of the present invention are capable of stimulating humoral and/or cell mediated immune responses. Heterologous antigens are targeted to appropriate pathways of MHC class I and class II antigen

- 23 -

processing and presentation, and are targeted for dendritic cells which initiate, in particular T-cell responses.

In another aspect, preferred L polypeptides comprise or consist of an amino acid sequence substantially set forth in SEQ ID NO: 7 and SEQ ID NO: 9, or an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.

Even more preferably, the % similarity exceeds 60% identity, more preferably 70% identity, still more preferably at least about 80%, still more preferably about 90-95% identity.

Preferred L polypeptides are derived from an avian hepadnavirus such as but not limited to DHBV. Importantly, the hepadnavirus or the envelope polypeptides employed in the present invention do not exclude L from VLP assembly.

Functional derivatives of the instant L polypeptide include fragments, parts or portions of the parent molecule which retain the ability of the L polypeptide to associate with the particle formed by S polypeptide, or at least where such ability is not substantially lost.

Functional derivatives of the instant S polypeptide retain the ability of the ability of the S polypeptide to form virus-like particles, or at least where such ability is not substantially lost.

Substantial loss would mean that the L particle is assembled with S in particles at a ratio of less than about 1:1 or more preferably less than about 1:2, even more preferably less than about 1:3, still even more preferably less than about 1:4.

A preferred S polypeptide is derived from an avian hepadnavirus such as but not limited to DHBV or comprises or consists of an amino acid sequence substantially set forth in SEQ ID NO: 13.

- 24 -

The term "functional derivative" also extends to polypeptides having one or more amino acid mutations or modifications. Mutations may be derived from additions, insertions, deletions or substitutions of amino acids. Substitutions are preferably conservative amino acid substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenyl alanine and tyrosine. Modifications may include the addition of flanking sequences which enhance viral particle assembly or stability.

Preferably, derivatives have at least 60% amino acid similarity, or more preferably at least 80%, or most preferably 90% or greater similarity to all or part of the parent molecules.

Accordingly, in another embodiment, the present invention provides a VLP comprising a fusion polypeptide comprising a POI and a particle associating portion of an L polypeptide wherein said L polypeptide comprises a sequence of amino acids substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or an amino acid sequence having at least about 50% similarity thereto, or a functional derivative or homolog thereof.

In another embodiment, the present invention provides a VLP comprising a fusion polypeptide comprising a POI and a particle associating portion of an L polypeptide wherein said L polypeptide is encoded by a sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or a sequence of nucleotides capable of hybridizing to SEQ ID NO: 6 or SEQ ID NO: 8, or a complementary form thereof under medium stringency conditions.

The VLPs of the present invention are assembled *in vitro* or *in vivo* using techniques which are well known to those of ordinary skill in the art such as those described or referred to herein or summarised in Sambrook *et al.* Specifically expression plasmids designed to express one or more recombinant envelope proteins as described herein are generated.

Accordingly, in another aspect, the present invention provides an isolated or recombinant polypeptide for use in the assembly of a VLP comprising a polypeptide of interest (POI)

- 25 -

and at least a particle-associating portion of a large envelope polypeptide (L) of an avian hepadnavirus such as DHBV or a functional derivative or homolog thereof.

In a related aspect, the present invention provides a recombinant polypeptide capable of assembling into a VLP when expressed in a cell, said polypeptide comprising a polypeptide of interest (POI) and at least a particle-associating portion of a large envelope polypeptide (L) of an avian hepadnavirus such as DHBV or a functional derivative of homolog thereof.

Preferably, the particle-associating portion of L comprises at least the S domain of L or the S domain of L minus the TM1 domain or a functional derivative thereof.

Still more preferably, the POI is located in the pre-S domain of L or at the amino terminal side of the S domain of L, or the S domain minus the TM1 domain of L.

In accordance with this aspect of the present invention, the L polypeptide comprises an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or comprises an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.

As described herein, the particle-associating portion of L polypeptide consists of an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or a functional derivative thereof comprising an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.

Avian hepadnaviruses exhibit considerable sequence identity and accordingly, sequences having greater than 70% similarity or identity are contemplated.

The present invention extends to the use in the manufacture of a VLP of an L polypeptide or particle associating portion thereof is encoded by a sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or having at least about 50% similarity to

- 26 -

SEQ ID NO: 6 or SEQ ID NO: 8 or a contiguous sequence of nucleotides capable of hybridizing to a complementary form SEQ ID NO: 6 or SEQ ID NO: 8 under hybridisation conditions of medium stringency.

- 5 In a further aspect of the invention, the L polypeptide further comprises a signal sequence. Such sequences are particularly useful in enhancing surface expression of a POI in the VLP.

Preferred L polypeptides are DHBV L polypeptide or functional derivative thereof.

10

- In yet another aspect, the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding a fusion polypeptide suitable for use in making a recombinant VLP, wherein said nucleic acid molecule encodes a POI and a particle associating portion of an L polypeptide and wherein the sequence of nucleotides encoding
15 the particle associating portion of an L polypeptide comprises the sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or a contiguous sequence of nucleotides capable of hybridizing thereto or to a complementary form thereof under low stringency hybridisation conditions, or a functional derivative or homolog thereof.

- 20 In yet still another aspect, the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding a fusion polypeptide suitable for use in making a recombinant VLP, wherein said nucleic acid molecule encodes a POI and a particle associating portion of an L polypeptide and wherein the nucleic acid encoding the particle associating portion of an L polypeptide encodes the amino acid sequence set forth
25 in SEQ ID NO: 7 or SEQ ID NO: 9 or an amino acid sequence having at least about 50% similarity thereto, or a functional derivative or homolog thereof.

- In another aspect, the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding a fusion polypeptide suitable for use in making a
30 recombinant VLP, wherein said nucleic acid molecule encodes a POI and a particle associating portion of an L polypeptide and wherein the nucleic acid encoding the particle

- 27 -

associating portion of an L polypeptide encodes the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 9

Yet another aspect of the present invention provides a recombinant nucleic acid molecule for use in making a recombinant VLP, said nucleic acid molecule comprising a sequence of nucleotides encoding at least a particle-associating portion of an L polypeptide of an avian hepadnavirus such as DHBV or a functional derivative or homolog thereof comprising one or more cloning sites suitable for accepting a second nucleic acid molecule encoding one or more polypeptide of interest, wherein said polypeptides of interest is expressed as a fusion polypeptide with said L polypeptide. The expression vectors of the present invention may also conveniently express other envelope proteins such as L or, preferably, S polypeptide. Thus bidirectional or bicistronic promoters may routinely be employed in order to express recombinant L and also S polypeptide from the same vector. In addition, signal sequences are employed to enhance expression including surface expression, of the POI. Cells and kits comprising the instant recombinant nucleic acid molecules are expressly encompassed.

The present invention therefore provides a method of delivering a POI to a subject or cell comprising expressing the POI in a VLP comprising L polypeptide from an avian hepadnavirus such as DHBV or a functional derivative or homolog thereof such that at least part of the POI is expressed on the surface of the VLP. In one aspect, the VLP is generated in an *in vitro* expression system. In another aspect, the VLP is generated *in vivo*. Where the POI is an antigenic polypeptide, the preferred cells are cells of the immune system such as antigen presenting cells.

Complementary forms of all or part the nucleic acid molecules of the present invention are expressly contemplated.

The terms "nucleic acids", "nucleotide" and "polynucleotide" include RNA, cDNA, genomic DNA, synthetic forms and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized

- 28 -

nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog (such as the morpholine ring), internucleotide modifications such as uncharged linkages (e.g. methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g. phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g. polypeptides), intercalators (e.g. acridine, psoralen, etc.), chelators, alkylators and modified linkages (e.g. α -anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence *via* hydrogen binding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels.

Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide and sequence comparisons are made at the level of identity rather than similarity.

Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence", "comparison window", "sequence similarity", "sequence identity", "percentage of sequence similarity", "percentage of sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 9 to 12 but frequently 15 to 18 and often at least 21 to 25 or above, such as 30 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of

- 29 -

the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to
5 identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal
10 alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated
15 by any of the various methods selected. Reference also may be made to the BLAST family of programs as, for example, disclosed by Altschul *et al*, *Nucleic Acid Research*, 25:3389-3402, 1997. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel *et al*, *supra*.

20 The terms "sequence similarity" and "sequence identity" as used herein refers to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of
25 positions at which the identical nucleic acid base (e.g. A, T, C, G, I) or the identical amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield
30 the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS

- 30 -

computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity. Conservative amino acid changes may be considered to provide similar sequences but not identical sequences.

Particularly preferred nucleic acid molecules encode a particle-associating portion of an L polypeptide and comprise a contiguous sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or a nucleotide sequence having at least about 50% similarity to SEQ ID NO: 6 or SEQ ID NO: 8. Preferably, the % similarity is in relation to the sequence encoding a particle-associating portion of L polypeptide.

Furthermore, the present invention contemplates nucleic acid molecules encoding a particle-associating portion of an L polypeptide comprising a sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or a nucleotide sequence capable of hybridizing to SEQ ID NO: 6 or SEQ ID NO: 8 or a complementary form thereof under medium stringency conditions.

Functional derivatives of the instant nucleic acid molecules include fragments thereof or sequences having one or more nucleotide mutations or modifications.

Mutations include one or more nucleotide deletions, insertions or substitutions. Alternatively or in addition, derivatives may be modified by the addition of sequences or moieties to enhance function such as enhanced stability or activity or to introduce new activity. For example, modifications may comprise the addition of fusagenic agents to enhance membrane permeability, modifications to affect pre or post-transcriptional modifications events, or to generate fusion proteins comprising labels, tags and other modifications for identification, purification and so forth.

- 31 -

Functional derivatives of the subject nucleic acid molecules retain the ability of the parent molecule to encode a polypeptide having the particle assembly function of S polypeptide or the particle associating function of L polypeptide.

Fragments of the nucleic acid molecules may include parts or one or more portions thereof, which have the function of the parent.

Functional homologs of the instant nucleic acid sequences include orthologous gene sequences from different species which are related by common phylogenic decent and also gene sequences from other species which are similar to the instant nucleic acid molecules as a result of convergent evolution, wherein the homologs are functionally and structurally related to the instant nucleic acid sequences and are consequently readily identified and/or isolated by hybridization based methods or by sequence comparison with published genome databases. For example, the nucleotide sequence of approximately 20 avian hepadnaviruses are publicly available (Triyatni *et al*, *J. Gen. Virol*, 82:373-378, 2001).

Similarity at the nucleic acid level may be assessed in assays exploiting different stringency of hybridization conditions as is well known in the art and is, for example, described in Ausubel *et al*, *supra*.

Reference herein to stringent hybridization conditions preferably means conditions which permit selective hybridization or annealing between molecules which are substantially similar. The hybridization temperature composition and ionic strength of the hybridization solution which meet this criteria will vary depending upon a number of well characterized factors such as length, degree of complementarity and GC content. For longer sequences it is generally possible to calculate the expected melting point of duplex nucleic acid sequences under various conditions. Hybridization may be to all or part of the instant polynucleotides with the minimum length being sufficient to provide specificity and functionality of their encoded polypeptides.

- 32 -

Low stringency hybridization conditions includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions.

Medium stringency includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing conditions. High stringency includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out $T_m = 69.3 + 0.41 (G+C\%)$. However, the T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base pairs (Bonner *et al*, 1974). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.

The recombinant nucleic acid molecules of the present invention which are suitable for use in making recombinant VLPs may be introduced into vectors to facilitate VLP production.

Vectors, preferably contain cloning sites and are capable of autonomous replication in a defined host cell. Alternatively, the vector may integrate into the genome and replicate together with the chromosome into which it has been introduced. Vectors generally also include selection markers.

Examples of selectable markers include genes conferring resistance to compounds such as antibiotics, genes conferring the ability to grow on selected substrates, genes encoding

- 33 -

proteins that produce detectable signals such as luminescence. A wide variety of such markers are known and available, including, for example, antibiotic resistance genes such as the neomycin resistance gene (*neo*) and the hygromycin resistance gene (*hyg*). Selectable markers also include genes conferring the ability to grow on certain media substrates such as the *tk* gene (thymidine kinase) or the *hprt* gene (hypoxanthine phosphoribosyltransferase) which confer the ability to grow on HAT medium (hypoxanthine, aminopterin and thymidine); and the bacterial *gpt* gene (guanine/xanthine phosphoribosyltransferase) which allows growth on MAX medium (mycophenolic acid, adenine and xanthine). Other selectable markers for use in mammalian cells and plasmids carrying a variety of selectable markers are described in Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbour, New York, USA, 1990.

The selectable marker may depend on its own promoter for expression and the marker gene may not necessarily be derived from human genomes (e.g. prokaryotic marker genes may be used in human cells). However, it is preferable to replace the original promoter with transcriptional machinery known to function in the recipient cells. A large number of transcriptional initiation regions are available for such purposes including, for example, metallothionein promoters, thymidine kinase promoters, β -actin promoters, immunoglobulin promoters, SV40 promoters and human cytomegalovirus promoters. A widely used example is the pSV2-*neo* plasmid which has the bacterial neomycin phosphotransferase gene under control of the SV40 early promoter and confers in mammalian cells resistance to G418 (an antibiotic related to neomycin). A number of other variations may be employed to enhance expression of the selectable markers in animal cells, such as the addition of a poly(A) sequence and the addition of synthetic translation initiation sequences. Both constitutive and inducible promoters may be used.

The recombinant nucleic acid molecule for use in making a recombinant VLP are preferably in kit form to facilitate introduction of a nucleic acid molecule encoding a POI and particle assembly.

- 34 -

Another aspect of the present invention provides an expression vector comprising a sequence of nucleotides encoding a POI and at least a particle-associating portion of an L polypeptide of DHBV or a functional derivative or homolog thereof wherein said POI is capable of being expressed as a fusion polypeptide with said L polypeptide.

Another aspect of the present invention provides an expression vector comprising a sequence of nucleotides encoding a POI and at least a part of the S domain of an L polypeptide of DHBV or a functional derivative or homolog thereof wherein the POI is expressed within or at a location N terminal to the S-domain of the L polypeptide amino acid sequence or functional derivative of homolog thereof.

Preferably, the POI is expressed N terminally of the S domain of L polypeptide or within the pre-S domain of L polypeptide.

As will be understood by those skilled in the art, the nucleic acid molecules of the present invention may be further modified to ensure their suitability for expression in a range of cells, selection *in vitro*, suitability for cloning various POIs therein. Such techniques and strategies are well known to those skilled in the art and may be conveniently referred to in Ausbel *et al*, *Eds short protocols in Molecular Biology*, John Wiley and Sons, 5th Edition, 2002 and/or Sambrook *et al*, *supra*.

To ensure expression, the nucleotide sequences encoding the POI and the L polypeptide components are operatively linked to one or more expression control sequences. Preferably the two or more such nucleotide sequences are in the same reading frame.

In one embodiment expression vectors are conveniently stably integrated into the genome of host cells and expression is driven by host cell promoters.

The present invention also extends to microorganisms or host cells transformed or transfected or otherwise comprising a nucleic acid molecules comprising a sequence of nucleotides encoding a POI and at least a particle-associating portion of an L polypeptide

- 35 -

of DHBV or a functional derivative or homolog thereof. Yeast cells are particularly convenient host cells. Prokaryotic or eukaryotic host cells are advantageously used. Typically prokaryotic cells include *E. coli*, *Bacillus sp* and eukaryotic cells include yeast, fungi, mammalian and insect cells.

The present invention furthermore provides a composition comprising a virus-like particle derived from DHBV L and S polypeptide for use as a vaccine wherein the L polypeptide comprises one or more antigens of interest.

The present invention also relates to a vaccine comprising an antigen of interest expressed as a fusion protein with a particle-associating L polypeptide of DHBV or a functional derivative or homolog thereof, and an S polypeptide of DHBV wherein the S polypeptide and antigen-L polypeptide are assembled into a VLP, in admixture with a suitable pharmaceutically acceptable diluent or carrier. The vaccine may be lyophilized prior to use and may furthermore be admixed with suitable adjuvants. Accordingly the vaccine may be in kit form.

By "pharmaceutically acceptable" carrier, or diluent is meant a pharmaceutical vehicle comprised of a material that is not biologically or otherwise undesirable, i.e. the material may be administered to a subject along with the selected active agent without causing any or a substantial adverse reaction. Carriers may include excipients and other additives such as diluents, detergents, coloring agents, wetting or emulsifying agents, pH buffering agents, preservatives, and the like.

The VLPs, and polypeptide nucleic acid molecules of the present invention can be formulated in pharmaceutical compositions which are prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing, Company, Easton, PA, U.S.A.). The composition may contain the active agent or pharmaceutically acceptable salts of the active agent. These compositions may comprise, in addition to one of the active substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well

- 36 -

known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. topical, intravenous, oral, intrathecal, epineural or parenteral.

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, International Patent Publication No. WO 96/11698.

For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.

The active agent is preferably administered in a therapeutically effective amount. The actual amount administered and the rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g.

- 37 -

decisions on dosage, timing, etc. is within the responsibility of general practitioners or specialists and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences, *supra*.

Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands or specific nucleic acid molecules. Targeting may be desirable for a variety of reasons, e.g. if the agent is self-antigenic or if it would not otherwise be able to enter the target cells.

Instead of administering these agents directly, they could be produced in the target cell, e.g. in a viral vector such as described below or in a cell based delivery system such as described in U.S. Patent No. 5,550,050 and International Patent Publication Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and WO 97/12635. The vector could be targeted to the target cells. The cell based delivery system is designed to be implanted in a patient's body at the desired target site and contains a coding sequence for the target agent. Alternatively, the agent could be administered in a precursor form for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. See, for example, European Patent Application No. 0 425 731A and International Patent Publication No. WO 90/07936.

Vaccine composition may alternatively comprise nucleic acid molecules encoding the recombinant VLPs.

Gene transfer systems known in the art may be useful in the practice of genetic manipulation. These include viral and non-viral transfer methods. A number of viruses have been used as gene transfer vectors or as the basis for preparing gene transfer vectors, including papovaviruses (e.g. SV40, Madzak *et al.*, *J. Gen. Virol.* 73: 1533-1536, 1992),

adenovirus (Berkner, *Curr. Top. Microbiol. Immunol.* 158: 39-66, 1992; Berkner *et al.*, *BioTechniques* 6: 616-629, 1988; Gorziglia and Kapikian, *J. Virol.* 66: 4407-4412, 1992; Quantin *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 2581-2584, 1992; Rosenfeld *et al.*, *Cell* 68: 143-155, 1992; Wilkinson *et al.*, *Nucleic Acids Res.* 20: 2233-2239, 1992; Stratford-Perricaudet *et al.*, *Hum. Gene Ther.* 1: 241-256, 1990; Schneider *et al.*, *Nature Genetics* 18: 180-183, 1998), vaccinia virus (Moss, *Curr. Top. Microbiol. Immunol.* 158: 25-38, 1992; Moss, *Proc. Natl. Acad. Sci. USA* 93: 11341-11348, 1996), adeno-associated virus (Muzyczka, *Curr. Top. Microbiol. Immunol.* 158: 97-129, 1992; Ohi *et al.*, *Gene* 89: 279-282, 1990; Russell and Hirata, *Nature Genetics* 18: 323-328, 1998), herpesviruses including HSV and EBV (Margolskee, *Curr. Top. Microbiol. Immunol.* 158: 67-95, 1992; Johnson *et al.*, *J. Virol.* 66: 2952-2965, 1992; Fink *et al.*, *Hum. Gene Ther.* 3: 11-19, 1992; Breakefield and Geller, *Mol. Neurobiol.* 1: 339-371, 1987; Freese *et al.*, *Biochem. Pharmacol.* 40: 2189-2199, 1990; Fink *et al.*, *Ann. Rev. Neurosci.* 19: 265-287, 1996), lentiviruses (Naldini *et al.*, *Science* 272: 263-267, 1996), Sindbis and Semliki Forest virus (Berglund *et al.*, *Biotechnology* 11: 916-920, 1993) and retroviruses of avian (Bandyopadhyay and Temin, *Mol. Cell. Biol.* 4: 749-754, 1984; Petropoulos *et al.*, *J. Virol.* 66: 3391-3397, 1992), murine [Miller, *Curr. Top. Microbiol. Immunol.* 158: 1-24, 1992; Miller *et al.*, *Mol. Cell. Biol.* 5: 431-437, 1985; Sorge *et al.*, *Mol. Cell. Biol.* 4: 1730-1737, 1984; Mann and Baltimore, *J. Virol.* 54: 401-407, 1985; Miller *et al.*, *J. Virol.* 62: 4337-4345, 1988] and human [Shimada *et al.*, *J. Clin. Invest.* 88: 1043-1047, 1991; Helseth *et al.*, *J. Virol.* 64: 2416-2420, 1990; Page *et al.*, *J. Virol.* 64: 5270-5276, 1990; Buchschacher and Panganiban, *J. Virol.* 66: 2731-2739, 1982] origin.

Non-viral gene transfer methods are known in the art such as chemical techniques including calcium phosphate co-precipitation, mechanical techniques, for example, microinjection, membrane fusion-mediated transfer *via* liposomes and direct DNA uptake and receptor-mediated DNA transfer. Viral-mediated gene transfer can be combined with direct *in vivo* gene transfer using liposome delivery, allowing one to direct the viral vectors to particular cells. Alternatively, the retroviral vector producer cell line can be injected into particular tissue. Injection of producer cells would then provide a continuous source of vector particles.

- 39 -

In an approach which combines biological and physical gene transfer methods, plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein and the resulting complex is bound to an adenovirus vector. The trimolecular complex is then used to infect cells. The adenovirus vector permits efficient binding, internalization and degradation of the endosome before the coupled DNA is damaged. For other techniques for the delivery of adenovirus based vectors, see U.S. Patent No. 5,691,198.

Liposome/DNA complexes have been shown to be capable of mediating direct *in vivo* gene transfer. While in standard liposome preparations the gene transfer process is non-specific, localized *in vivo* uptake and expression have been reported in tumor deposits, for example, following direct *in situ* administration.

General methods for generating the viral particles of the present invention are well known to skilled practitioners.

The present invention provides a method of preparing a recombinant VLP said method comprising:

- i) cloning a nucleic acid molecule encoding a polypeptide of interest into an expression vector comprising a particle-associating portion of an L polypeptide of DHBV or a functional derivative or homolog thereof;
- ii) infecting or transfecting a suitable cell with the recombinant expression vector of step i) under conditions which allow protein expression and particle assembly with S polypeptide of DHBV or a functional derivative or homolog thereof;
- iii) recovering said virus-like particles from said cells.

Yeast cells, for example, will be transformed with L/POI and S expression plasmids. Preferably, expression is driven by a yeast promoter and expressed in yeast cells, such as a strain of *Saccharomyces*.

- 40 -

Another aspect of the present invention is directed to antibodies to the fusion polypeptides of the present invention. Antibodies may be monoclonal or polyclonal and technique for their manufacture are very well known. Antibodies which specifically recognise determinants of the fusion polypeptide of the present invention are particularly preferred.

The present invention is further described by the further non-limiting Examples.

- 41 -

EXAMPLE 1**Substitution of a.a.45-125 of DHBV preS with
the N terminal 82 amino acids of the ectodomain of HCV E2 by Fusion PCR**

Plasmid pCDL-E2.465 encodes a chimeric L protein consisting (from N to the C terminus) of DHBV L aa 1-4; HCV E2 aa 384 to 465; DHBV L aa 126 to 328. This represents an insertion of a protein of interest of 82 amino acids. Fusion PCR (overlap extension PCR) was used as described by Ho *et al*, *Gene*, 77:51, 1989. Overlapping primers were each paired with an outside primer complementary to the plus strand of pCDL-w.t. or the minus strand of HCV construct in 2 first round PCR reactions using pfu enzyme. The PCR products (153 bp from pCDL as template and 272 bp with the HCV template) from each reaction were purified using a Qiagen min elute kit and the two purified products used as the template for the fusion PCR reaction using the outside primers. The 578 bp fusion PCR product was purified and digested with XmaI, cutting at nt 1743 of the HCV primer sequence and with Aat II, cutting at nt 831 of DHBV L. The plasmid, pMDL-w.t., carrying unique XmaI and Aat II sites in the DHBV preS coding sequence was used as vector. The digested PCR fragment and the large fragment of the cut vector were excised from an agarose gel and purified using a Prep-a-gene kit (Bio-Rad). Competent cells (DH5 α cells) were transformed with the ligated plasmid and transformants selected from ampicillin plates.

Positive clones were detected by restriction enzyme digestion of purified DNA using a restriction site which is also present in the HCV E2 ectodomain sequence (BsaI).

A SalI/Xho I fragment of pMDL-E2 containing the E2 insert was subcloned into pCDL-w.t. (DHBV L expression plasmid with CMV promoter) using the same unique restriction sites (see Figure 1). Bsa I digestion was used again to confirm the presence of the E2 insert in pCDL-E2.465. The CDL-E2.465 clone was also confirmed by sequencing, covering the region of preS-E2-preS and part of S to nucleotide 1581.

- 42 -

Outside Primers**P804**

5' GGGCAACATCCAGCAAAATCAATGG 3' (SEQ ID NO: 1 DHBV nt 804-828)

P-1719

5' GCTGCGGAATGGCTAAAAGGGCCCCCGACC 3' (SEQ ID NO: 2 HCV nt 1719-1749 with an XmaI RE site inserted, shown underlined)

Overlapping Chimeric Primers (plain type= DHBVpreS; bold= HCV E2)**P1492** (refers to nt at start of E2 sequence)CCAACACTAGATCACG**AA**ACCCACGTCACCGGGG (SEQ ID NO: 3)**P-1492**GGTTGTGATCTAGTG**C**TTTGGGTGCAGTGGCCCC (SEQ ID NO: 4)**Templates:**

pCDL-wt (DHBV L expression plasmid); p90/HCV FL-longpU

EXAMPLE 2**Expression and Analysis of CDL-E2 in avian Hepatoma (LMH) cells**

The avian hepatoma cell line, LMH was co-transfected with 5 µg each of pCDL-E2.465 and pCI-S (Gazina *et al*, *Virology* 242:266, 1998) using the dextran sulphate method (Grgacic *et al*, *J.Gen. Virol.* 79:2743, 1998). Day 3 post-transfection media were collected for assessment of exported particles and cells either processed for cytosolic fractionation and assessment of intracellular particle formation or isolation of microsomes for protease

- 43 -

protection analysis or isolation of the membrane fraction for assessment of protein expression (Grgacic, *J.Gen. Virol.* 83:1635, 2002).

EXAMPLE 3

Isolation of Intracellular and Extracellular Particles

- (i) Extracellular particles: Media from transfected LMH cells was harvested day 3 post-transfection and clarified of non-adherent cells by centrifugation for 5 min at 2,000 rpm.
- (ii) Intracellular particles: Cell monolayers were washed twice with PBS and harvested by scraping cells into 1 ml PBS. Harvested cells were freeze/thawed three times with vigorous vortexing upon thawing. The cytosol fraction (supernatant) was obtained by centrifugation for 1 min at 10,000 rpm in an Eppendorf centrifuge. This procedure has been used in this laboratory to release DHBV particles from transfected cells capable of infecting primary duck hepatocytes.

Particles in the clarified media or cytosol fraction were diluted to 6 ml with PBS and pelleted for 3 h at 38,000 rpm in an SW40 rotor (Beckman) through 3 ml of 20% sucrose onto a 2 ml 70% sucrose cushion. The fraction at the 20-70% interface was collected from the bottom, methanol precipitated for 16 h at -20°C followed by separation on 13% SDS-PAGE and Western blotting.

As shown in Figure 2D, Western Blot show that the E2.465/L chimera is assembled into particles. Intracellular particles were isolated from avian hepatoma (LMH) cells transfected with pCDL-E2.465 and pCI-S by freeze-thawing cells 3 times, centrifugation to obtain the cytosolic fraction for sedimentation of particles through 20% sucrose on to a 70% sucrose cushion at 38,000 r.p.m. (SW41 rotor Beckman). The particle fraction at the 20-70% sucrose interface was methanol precipitated prior to SDS-PAGE and analysis of envelope proteins by Western blotting.

- 44 -

EXAMPLE 4

Protease Protection Analysis

Microsomes were prepared according to the method of Prange and Streeck, *EMBO J.* 14:247, 1995 with modifications. Transfected LMH cells (two 30mm diameter wells) were washed in cold Tris-buffered saline (TBS: 50mM Tris-HCl, pH 7.5; 150mM NaCl).

The monolayers in each well were incubated on ice with 0.4 ml 0.1X TBS for 10 minutes and then harvested by scraping, pooled and dispersed by drawing 5 times through a 26G needle. The homogenate was adjusted to 1X TBS with 5X TBS and centrifuged for 20 min at 2,500 rpm at 4°C to remove unbroken cells and nuclei. The supernatant was removed and set aside while the pellet was again dispersed in 300µl TBS and centrifuged as before.

Supernatants were pooled and layered onto 2.7ml 250mM sucrose in TBS and centrifuged for 30min. at 38,000rpm at 4°C in an SW-60 rotor (Beckman). The microsomal pellets were washed once with TBS and resuspended in 65µl TBS.

For trypsin protection analysis the microsomal preparation was divided into three 20 µl aliquots. One sample was left untreated while the remaining two were treated with 25µg/ml of trypsin (TPCK treated; Worthington Biochem. Corp. NJ, USA) with or without 0.5% NP-40 for 1 h. on ice.

EXAMPLE 5

Western blot analysis

Proteins were separated by SDS-PAGE (13% acrylamide) and transferred to nitrocellulose membrane (Schleicher and Schüll) using a Trans-Blot SD semi-dry transfer cell (Biorad). Membranes were blocked for 1 h with 3% skim milk in PBS plus 0.3% Tween 20 (PBST). Membranes were probed with monoclonal anti-S (7C.12) (Pugh *et al*, *J. Virol.* 69:4814, 1995) for 1 h in 1% skim milk; PBST, then washed with PBST and probed with goat anti-mouse Ig:horse radish peroxidase (Amersham) in 1% skim milk PBST. After a final wash

- 45 -

in PBST (3x10 min.) proteins bands were visualised by enhanced chemiluminescence (ECL) (Amersham).

As shown in Figure 2C, Western Blot show that the E2.465/L chimera is translocated across the ER. Protease protection analysis of ER microsomes prepared from LMH cells transfected with pCDL-E2.465 and pCI-S (an S protein expression plasmid). Microsomes samples were subjected to digestion with trypsin in the absence or presence of the detergent, NP-40, or left untreated, as denoted above each lane. Protease protection of E2.465/L chains was analysed by SDS-PAGE and Western blotting with a monoclonal anti-S antibody, which detects both E2.465/L and S proteins. Protection of E2.465/L from trypsin digestion (middle lane) is an indication of translocation to the ER lumen.

EXAMPLE 6

Construction of strategically selected chimeric DHBV VLPs to define their carrying capacity as a potential vaccine delivery vehicle

The receptor binding region as well as the C terminus of preS is exposed to the DHBV subviral particle surface. These exposed regions, flanked by the membrane spanning S domain, are believed to be further stabilised through anchorage at the N terminus by the myristylation signal. The HCV E2 ectodomain inserted into this region of preS was similarly exposed and stabilised. PreS sequences are substituted by equivalent or larger sized foreign sequences or alternatively fused in frame to the N terminus of the S domain of L by fusion PCR.

To aid translocation of the chimeric L polypeptides, an L construct with a signal sequence such as the preprolactin signal sequence fused to the N terminus, which causes co-translational translocation of L, is also used. These SigL chains can assemble with S subunits and be exported as particles. Translocation of the chimeric preS domains is monitored by the protease protection assay and antibody mapping of the topology on the assembled particle by immunoprecipitation. Particles are purified by sucrose gradient sedimentation and analysed by EM/immunogold labelling for VLP formation. Pulse-chase

- 46 -

metabolic labelling are performed to assess that the proportion of recombinant chains relative to S (approximately 1:4 for wild type DHBV) is maintained in the assembled particle.

EXAMPLE 7

Construction and analysis of the E2.465/L chimera with TM1 deleted in L

pCDL Δ TM1-E2.465 encodes a chimeric L protein consisting (from the N to the C terminus) of DHBV L a.a. 1-45; HCV E2 a.a. 384-465; DHBV L a.a.126-328 with a deletion of 18 a.a. of transmembrane domain 1 at a.a.168-186 (see Figure 5B). This represents an insertion of a protein of interest of 82 a.a.

pCDL Δ TM1-E2.465 was constructed by subcloning a Sal I/BstEII fragment (encompassing preS/E2 and S domain sequences) of pMDL Δ TM1-E2.465 into pCDL-w.t. Transfer of the insert was confirmed by restriction enzyme digestion with Bsa I. Expression and analysis of pCDL Δ TM1-E2.465 was done in LMH cells as described in Examples 2, 3 and 4. Expression of the E2.465/L Δ TM1 chimera both as protein and as assembled particles, was greater than that observed with the pCDL-E2.465 plasmid. Constructs with the TM1 deletion can be used for all chimeric DHBV VLPs, if required.

EXAMPLE 8

Construction of an E2.465/L Δ TM1 chimera with an N terminal signal sequence (preprolactin)

pSigL Δ TM1-E2.465 encodes a chimeric L protein consisting (from the N to the C terminus) Preprolactin signal sequence a.a.1-26; DHBV L a.a. 2-45; HCV E2 a.a. 384-465; DHBV L a.a.126-328 with a deletion of 18 a.a. of transmembrane domain 1 at a.a.168-186 (see Figure 5D). This represents an insertion of a protein of interest of 82 amino acids.

- 47 -

Signal sequences fused to the N terminus of DHBV L cause the L protein to be co-translationally translocated across the ER membrane which in turn results in glycosylation of the L protein (Swaymeyer and Schaller, *J. Virol.*, 71:9434, 1997; Gazina *et al.*, (*supra*)).

Firstly, pCDSigLΔTM1-E2.465 was constructed by sequential subcloning, first of an AatII/Kpn I fragment of pMDLΔTM1-E2.465 into pMDSigLΔTM1-E2.465 and then a Sal I/BstEII fragment of the latter into pCDSigLΔTM1-E2.465. A PpuMuI/BstEII fragment from pCDSigLΔTM1-E2.465 containing the E2.465 sequences was subcloned into the same sites in PPL-L, encoding the preprolactin signal sequence at the N terminus of DHBV L (Gazina *et al.*, (*supra*)). The resulting plasmid was assigned the name, pSigLΔTM1-E2.465. pSigLΔTM1-E2.465 expressed the chimeric L-E2.465 protein at similar levels to the PPL-L protein when examined as in Example 2.

EXAMPLE 9

Construction and analysis of the E2.661/L chimera comprising the entire ectodomain of HCV E2

pSigLΔTM1-E2.661 encodes a chimeric L protein consisting (from the N to the C terminus) Preprolactin signal sequence a.a.1-26; DHBV L a.a. 2-45; HCV E2 a.a. 384-661; DHBV L a.a.168-328 (see Figure 5E). This represents an insertion of a protein of interest of 278 amino acids.

The E2.661/L chimera incorporates a.a. 384-661 of HCV E2, i.e., the 278 amino acid ectodomain of E2 into the preS domain of DHBV L. The E2.661/L was constructed by PCR using a primer to the sequence at the start site of HCV E2 (nt 1490) and reverse primer covering nt 2321 at the end of the ectodomain of E2 and incorporating a Kpn I restriction enzyme site. The PCR product was digested with Nae I (nt 1517 of E2) and Kpn I and inserted into the same sites in pCDLΔTM1-E2.465 to create pCDLΔTM1-E2.661. Incorporation of the PPL signal sequence to this construct was done by a three-way ligation of the following fragments: a NarI/BstE II fragment of pCDLΔTM1-E2.661 encompassing the E2 sequence; a Bgl II/ Nar I fragment of the pSigLΔTM1-E2.465

- 48 -

encompassing the preprolactin sequence and part of E2 and a Bgl II/BstE II fragment of PPL-L providing the remaining vector sequences. Expression of the resulting construct pSigL Δ TM1-E2.661 was shown in LMH cells as described in Example 2 (see Figure 6A).

EXAMPLE 10

Construction and analysis of HBVpreS/L and HBVpreS/L Δ chimeras

pCDL-HBVpreS encodes a chimeric L protein consisting (from the N to the C terminus) of HBV preS a.a. 1-163; DHBV L a.a.162 -328. pCDL Δ -HBVpreS encodes a chimeric L protein consisting (from the N to the C terminus) of HBV preS a.a. 1-163; DHBV L a.a.162 -328 with a deletion of 18 a.a. of transmembrane domain 1 at a.a.168-186 (see Figure 5F to 5G). These constructs represents an insertion of a protein of interest of 163 amino acids.

Genome sequences encoding the preS domain (a.a.1-163) of HBV (strain *ayw*) and the S domain of DHBV were amplified by PCR from plasmids encoding the respective L proteins, then joined by fusion PCR. The HBV preS primer introduced a Sal I restriction site upstream of the initiation of HBV preS. The fusion PCR product was digested using Sal I and a BstEII restriction site in the DHBV sequence upstream of the DHBV primer and ligated into the same sites in pCDL-w.t. to create the pCDL-HBVpreS plasmid. The HBV preS sequence, which has no sequence homology with the DHBV preS (Sprengel *et al*, *J. Med. Virol.*, 15:323, 1985), is thus directly fused to the S domain of DHBV L in these constructs.

pCDL Δ -HBVpreS was constructed by a three-way ligation of the following fragments: a SalI/KpnI fragment of pCDL-HBVpreS encompassing the HBV preS sequence, a KpnI/BstEII fragment of pCDL Δ TM1 encompassing the DTM1 region and a Sal I/BstEII fragment of pCDL-w.t. providing the remaining vector sequences.

Expression and analysis of pCDL-HBVpreS and pCDL Δ -HBVpreS was done in LMH cells as described in Examples 2, 3 and 4.

EXAMPLE 11

Construction and analysis of the *P. falciparum* MSP2/L Δ TM1 chimera

pCDL Δ TM1-MSP2 encodes a chimeric L protein consisting (from the N to the C terminus) of DHBV L a.a.1-30; *P. falciparum* MSP2 a.a. 20-249; DHBV L a.a.126-328 with a deletion of 18 a.a. of transmembrane domain 1 at a.a.168-186 (see Figure 5H). This represents an insertion of a protein of interest of 230 amino acids.

The malaria pathogen, *Plasmodium falciparum* (isolate NF54 clone 3D7) MSP2 gene was cloned by fusion PCR. Two sets of primers were used for generating separate templates for fusion. The first set encompassed a forward primer incorporating the SalI restriction enzyme site of pCDL Δ TM1 and a reverse primer overlapping the first 27bp of MSP2 and the second set consisted of a forward primer overlapping DHBV L and a reverse primer incorporating a XmaI restriction enzyme site into MSP2. The separate templates were then joined by fusion PCR, restricted by SalI and XmaI and ligated into the vector. The ligated insert-vector was transformed into *E. coli* DH5 alpha, creating the chimeric vector pCDL Δ TM1 - MSP2. Expression of the resulting construct was shown in LMH cells as described in Example 2 (see Figure 6B).

EXAMPLE 12

Production of DHBV VLPs in *Saccharomyces cerevisiae*

For the purposes of scaling-up production of recombinant DHBV VLPs and chimeric DHBV VLPs for immunisation studies, a yeast inducible expression system was used. DHBV DNA encoding the large envelope protein was cloned into the pYES2 vector (Invitrogen) by PCR using a primer to the sequence upstream (starting at nt 762) of the start site of DHBV L (nt 801) and incorporating a Sac I restriction enzyme site and a reverse primer covering nucleotide 1910 and incorporating an Eco R1 restriction site. The PCR product was digested and inserted into the SacI and EcoR1 sites in the multicloning site of the vector. The pYES2 vector carries an ampicillin resistance gene for selection of

- 50 -

clones in *E.coli*. Clones containing the DHBV L gene (pYES-DL) were confirmed by restriction enzyme digestion and one was selected for transformation of the yeast strain, INVSc1.

A yeast expression plasmid for DHBV S gene expression, pMB-DS (Klingmüller and Schaller, *J. Virology*, 67:7414, 1993), was used for co-transformation of the INVSc1 strain with pYES-DL. The pYES2 vector carries a URA3 gene for selection of transformants in yeast and pMB-DS carries a LEU2 selection marker. The INVSC-1 stain used will not grow in media deficient in leucine, uracil, histidine and tryptophan. Co-transformants were therefore selected for growth on media lacking both leucine and uracil. Transformation of competent INVSc-1 cells was done according to the manufacturer's (INVITROGEN) instructions. Both plasmids have a GAL1 promoter for high level inducible protein expression in yeast by galactose and repression by glucose. Transformants were grown in yeast synthetic drop-out media without uracil and leucine (SC-UL) with 2% glucose for 2 days and then induced for protein expression by the substitution of glucose with 2% galactose and grown in YEP (1% yeast extract; 2% peptone) media for a further 24-48 hours.

DHBV L and S protein expression was examined by Western blotting following extraction of protein in yeast cells with acid-washed glass beads and vigorous vortexing followed by centrifugation. Supernatants were analysed by Western blotting with anti- S monoclonal as described in Example 5. Transformants (DL/S), which expressed the greatest amount of L and S protein were selected and stored as glycerol stocks.

For analysis of DHBV VLP production: A 50 ml yeast culture of DL/S was extracted and the supernatant loaded onto 20% sucrose above a 70% sucrose cushion and centrifuged at 38,000 rpm for 3 hours in a SW41 rotor (Beckman). The fraction at the 20-70% interface was then loaded onto a 20-70% sucrose step gradient and centrifuge for 5 hours at 38,000 rpm (Grgacic and Schaller, *J. Virol.*, 74:5116, 2000). Fractions were collected from the bottom of the gradient and analysed by Western blotting. Serum-derived DHBV subviral particles sediment at approximately 30% sucrose (peak fractions 7 and 8). The yeast-

- 51 -

derived DHBV VLPs were similarly shown to sediment largely at 30% sucrose (see Figure 7A).

Transmission Electron Microscopy (TEM) of yeast-derived particles was conducted by the Monash Micro Imaging Facility. Particles for TEM were sucrose gradient purified and further buffer exchanged with phosphate buffered saline using a Vivaspin 20 desalting and concentration device (Vivascience) prior to negative staining with uranyl acetate. A comparison of TEM of serum-derived DHBV subviral particles and yeast-derived DL/S particles showed similar particle morphology and size (approx 40-60nm).

Variations on the pYES-DL construct to include the deletion in transmembrane domain 1 and the preprolactin Signal sequence with and without the deletion in transmembrane domain 1 were made. pYES-DL Δ TM1 was constructed by subcloning an Aat II/Bst EII fragment of pMDL Δ TM1 containing the region of the TM1 deletion into pYES-DL using the same restriction enzyme sites. pYES-SigL was constructed by subcloning a Sac I/Bst EII fragment of PPL-L containing the signal sequence into pYES-DL using the same restriction sites. pYESSigL Δ TM1 was constructed by subcloning an Aat II/BST Eii fragment of pMDL Δ TM1 containing the TM1 deleted region into pYES-SigL using the same restriction sites. VLP production and analysis in yeast was done as described above. DL Δ TM1/S, SigL/S and SigL Δ TM1/S VLPs were shown to have the same sedimentation profile as DL/S particles in a sucrose step gradient.

EXAMPLE 13

Production of chimeric DHBV VLPs in *Saccharomyces cerevisiae*

pYES-DL-E2.465 and pYES-DL Δ TM1-E2.465 were constructed by subcloning E2 encompassing sequences from pMDL Δ TM1-E2.465 in an Aat II/XmaI fragment for the former and an Aat II/Bst EII fragment for the latter into the same sites in pYES-DL. INVSc-1 cell were co-transformed with either pYES-DL-E2.465 and pMB-DS or pYES-DL Δ TM1-E2.465 and pMB-DS for chimeric particle production and analysis in yeast as described in Example 11. The DL Δ TM1-E2.465 VLPs were shown to have the same

- 52 -

sedimentation profile as DL/S particles in a sucrose step gradient (see Figure 7B) and have a similar morphology to DL/S particles by TEM.

pYES-DL Δ TM1-HpreS was constructed by PCR using a primer to the sequence upstream (starting at nt 4091) of the start site of HBV preS (nt 4138) and incorporating a Sac I restriction enzyme site and a reverse primer covering nucleotide 1910 of the DHBV sequence and incorporating an Eco R1 restriction site. The PCR product was digested and inserted into the SacI and EcoRI sites in the multicloning site of the PYES vector. Chimeric particle production and analysis in yeast was done as described in Example 11. DL Δ TM1-HpreS VLPs were shown to have the same sedimentation profile as DL/S particles in a sucrose step gradient (see Figure 7C) and have a similar morphology to DL/S particles by TEM.

EXAMPLE 14

Analysis of immunogenicity of DHBV VLPs produced in yeast

DL/S VLPs were used to immunize rats. DL/S VLP production: A 100 ml yeast culture of DL/S was extracted and the supernatant loaded onto two 20% sucrose above a 70% sucrose cushion and centrifuged at 38,000 rpm for 3 hours in a SW41 rotor (Beckman). The portion of the pelleted VLPs was examined by SDS-PAGE and Coomassie Brilliant Blue protein staining against a standard protein to estimate the amount of VLP protein. Approximately 10 μ g doses of DL/S in a total of 200 μ l were injected in rats i.m. Rats were put into three groups of six rats with each group receiving DL/S VLPs either without the addition of an adjuvant or with the addition of alum or Titremax. Rats were bled 3 weeks following immunisation and subsequent boosts. Analysis of rat sera by Western blotting of DHBV L/S protein showed a strong and rapid immunoreactivity without the presence of adjuvant to the DHBV L protein with little or no response to DHBV S protein (see Figure 8).

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood

- 53 -

that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

- 54 -

BIBLIOGRAPHY

Altschul *et al*, *Nucleic Acid Research*, 25:3389-3402, 1997.

Ausbel *et al*, *Eds short protocols in Molecular Biology*, John Wiley and Sons, 5th Edition, 2002.

Bandyopadhyay and Temin, *Mol. Cell. Biol.* 4: 749-754, 1984.

Berglund *et al.*, *Biotechnology* 11: 916-920, 1993.

Berkner *et al.*, *BioTechniques* 6: 616-629, 1988.

Berkner, *Curr. Top. Microbiol. Immunol.* 158: 39-66, 1992.

Bisht, H., D. A. Chugh, M. Rajee, S. Swaminathan, and N. Khanna. *J. Biotechnology*. 99:97-110, 2002.

Bonner *et al*, Functional organisation of the mammalian genome CSHSQB, 38:308-10, 1974.

Breakefield and Geller, *Mol. Neurobiol.* 1: 339-371, 1987.

Bruss, V., and D. Ganem. *J. Virol.* 65:3813-3820, 1991.

Bruss *et al.*, *EMBO J.*, 13:2273-2279, 1994.

Buchschacher and Panganiban, *J. Virol.* 66: 2731-2739, 1982.

Delpeyroux, F., N. Chenciner, A. Lim, M. Lambert, Y. Malpiece, and R. E. Streek. *J. Mol. Biol.* 195:343-350, 1987.

- 55 -

Fink *et al.*, *Ann. Rev. Neurosci.* 19: 265-287, 1996.

Fink *et al.*, *Hum. Gene Ther.* 3: 11-19, 1992.

Frazer, I. *Virus Research.* 89:271-274, 2002.

Freese *et al.*, *Biochem. Pharmacol.* 40: 2189-2199, 1990.

Gazina *et al.*, *Virology* 242:266, 1998.

Gorziglia and Kapikian, *J. Virol.* 66: 4407-4412, 1992.

Grgacic *et al.*, *J. Gen. Virol.* 79:2743, 1998.

Grgacic, *J. Gen. Virol.* 83:1635, 2002.

Grgacic and Schaller, *J. Virol.*, 74:5116, 2000.

Helseth *et al.*, *J. Virol.* 64: 2416-2420, 1990.

Ho *et al.*, *Gene*, 77:51, 1989.

Johnson *et al.*, *J. Virol.* 66: 2952-2965, 1992.

Klingmuller, U., and H. Schaller. *J Virol.* 67:7414-7422, 1993.

Krueger, D. H., R. Ulrich, and W. H. Gerlich. *Biol. Chem.* 380:275-276, 1998.

Lenhoff, R., and J. Summers. *J. Virol.* 68:4565-4571, 1994.

- 56 -

Madzak *et al.*, *J. Gen. Virol.* 73: 1533-1536, 1992.

Mann and Baltimore, *J. Virol.* 54: 401-407, 1985.

Margolskee, *Curr. Top., Microbiol. Immunol.* 158: 67-95, 1992.

Miller *et al.*, *J. Virol.* 62: 4337-4345, 1988.

Miller *et al.*, *Mol. Cell. Biol.* 5: 431-437, 1985.

Miller, *Curr. Top. Microbiol. Immunol.* 158: 1-24, 1992.

Moss, *Curr. Top. Microbiol. Immunol.* 158: 25-38, 1992.

Moss, *Proc. Natl. Acad. Sci. USA* 93: 11341-11348, 1996.

Muzyczka, *Curr. Top. Microbiol. Immunol.* 158: 97-129, 1992.

Naldini *et al.*, *Science* 272: 263-267, 1996.

Nassal, M. *Curr. Top. Microbiol. Immunol.* 214:297- 337, 1996.

Netter, H. J., T. B. MacNaughton, W.-P. Woo, R. Tindle, and E. J. Gowans. *J. Virol.* 75:2130-2141, 2001.

Ohi *et al.*, *Gene* 89: 279-282, 1990.

Page *et al.*, *J. Virol.* 64: 5270-5276, 1990.

Petropoulos *et al.*, *J. Virol.* 66: 3391-3397, 1992.

- 57 -

Pugh *et al.*, *J. Virol.* 69:4814, 1995.

Prange, R., M. Werr, M. Birkner, R. Hilfrich, and R. E. Streeck. *J. Gen. Virol.* 76:2131-2140, 1995.

Prange and Streeck, *EMBO J.* 14:247, 1995.

Quantin *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 2581-2584, 1992.

Rosenfeld *et al.*, *Cell* 68: 143-155, 1992.

Russell and Hirata, *Nature Genetics* 18: 323-328, 1998.

Sambrook *et al.* "Molecular Cloning: A Laboratory Manual" Cold Spring Harbor Laboratory, 3rd Edition, 2001.

Schneider *et al.*, *Nature Genetics* 18: 180-183, 1998.

Shimada *et al.*, *J. Clin. Invest.* 88: 1043-1047, 1991.

Sorge *et al.*, *Mol. Cell. Biol.* 4: 1730-1737, 1984.

Sprengel *et al.*, *J. Med. Virol.*, 15:323, 1985.

Stratford-Perricaudet *et al.*, *Hum. Gene Ther.* 1: 241-256, 1990.

Swaymeyer and Schaller, *J. Virol.* 71:9434, 1997.

Triyatni *et al.*, *J. Gen. Virol.* 82:373-378, 2001.

Wilkinson *et al.*, *Nucleic Acids Res.* 20: 2233-2239, 1992.

Claims:

1. A virus-like particle (VLP) comprising i) a fusion polypeptide comprising a polypeptide of interest (POI) and a particle-associating portion of a hepadnavirus large envelope polypeptide (L) or a functional derivative or homolog thereof and ii) a hepadnavirus small envelope (S) polypeptide or a functional derivative or homolog thereof.
2. The VLP of claim 1 comprising a fusion polypeptide comprising a polypeptide of interest (POI) and a particle-associating portion of a large envelope polypeptide (L) of an avian hepadnavirus, such as duck hepatitis B virus (DHBV), or a functional derivative thereof.
3. The VLP of claim 1 or 2 comprising a fusion polypeptide comprising a polypeptide of interest (POI) and a particle-associating portion of a large envelope polypeptide (L) of an avian hepadnavirus, such as duck hepatitis B virus (DHBV), or a functional derivative thereof and ii) a small envelope (S) polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof.
4. The VLP of claim 1 or 2 wherein the particle-associating portion of L comprises at least the S domain of L, or the S domain of L minus the TM1 domain, or a functional derivative thereof.
5. The VLP of claim 1 or 2 wherein the POI is located in the pre-S domain of L or at the amino terminal side of the S domain of L, or the S domain minus the TM1 domain of L.
6. The VLP of claim 1 or 2 wherein the L polypeptide comprises an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or a functional derivative thereof or comprises an amino acid sequence having at least

- 59 -

50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.

7. The VLP of claim 1 or 2 wherein the particle-associating portion of L polypeptide comprises an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or a functional derivative thereof comprising an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.
8. The VLP of claim 1 or 2 wherein the particle-associating portion of L-polypeptide comprises or consists essentially of amino acids 24 to 107 of SEQ ID NO: 9 or an amino acid sequence having at least 50% similarity thereto.
9. The VLP of any one of claims 1 to 9 wherein the L polypeptide is a DHBV L polypeptide or functional derivative thereof.
10. The VLP of claim 1 or 2 wherein said L polypeptide or particle-associating portion thereof is encoded by a sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or having at least about 50% similarity to SEQ ID NO: 6 or SEQ ID NO: 8 or a contiguous sequence of nucleotides capable of hybridizing to a complementary form of SEQ ID NO: 6 or SEQ ID NO: 8 under hybridisation conditions of medium stringency.
11. The VLP of claim 1 or 2 wherein the L polypeptide further comprises a signal sequence.
12. An isolated or recombinant polypeptide for use in the assembly of a VLP, comprising a polypeptide of interest (POI) and at least a particle-associating portion of a large envelope polypeptide (L) of an avian hepadnavirus, such as DHBV, or a functional derivative thereof, wherein the POI is not a pre-S region of an avian hepadnavirus.
13. A recombinant polypeptide capable of assembling into a VLP when expressed in a

- 60 -

cell comprising a polypeptide of interest (POI) and at least a particle-associating portion of a large envelope polypeptide (L) of an avian hepadnavirus such as DHBV or a functional derivative thereof, wherein the POI is not a pre-S region of an avian hepadnavirus.

14. The polypeptide of claim 12 or 13 wherein the particle-associating portion of L comprises at least the S domain of L, or the S domain of L minus the TM1 domain, or a functional derivative thereof.
15. The polypeptide of claim 12 or 13 wherein the POI is located in the pre-S domain of L or at the amino terminal side of the S domain of L, or the S domain minus the TM1 domain of L.
16. The recombinant or isolated polypeptide of claim 12 or 13 wherein the L polypeptide comprises an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or a functional derivative thereof or comprises an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.
17. The recombinant or isolated polypeptide of claim 12 or 13 wherein the particle-associating portion of L polypeptide consists of an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or a functional derivative thereof comprising an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.
18. The recombinant or isolated polypeptide of claim 12 or 13 wherein the particle associating portion of L-polypeptide comprises or consists essentially of amino acids 24 to 107 of SEQ ID NO: 9 or an amino acid sequence having at least 50% similarity thereto.
19. The recombinant or isolated polypeptide of claim 12 or 13 wherein said polypeptide or particle-associating portion thereof is encoded by a sequence

- 61 -

nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or having at least about 50% similarity to SEQ ID NO: 6 or SEQ ID NO: 8 or a contiguous sequence of nucleotides capable of hybridizing to a complementary form of SEQ ID NO: 6 or SEQ ID NO: 8 under hybridisation conditions of medium stringency.

20. The recombinant or isolated polypeptide according to claim 12 or 13 wherein said L polypeptide further comprises a signal sequence.
21. The recombinant or isolated polypeptide of claim 12 or 13 wherein the L polypeptide is a DHBV L polypeptide or a functional derivative thereof.
22. A recombinant nucleic acid molecule for use in making a VLP, said nucleic acid molecule comprising a contiguous sequence of nucleotides encoding a polypeptide of interest (POI) and at least a particle-associating portion of an L polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof, wherein the POI is not a pre-S region of an avian hepadnavirus.
23. A recombinant nucleic acid molecule for use in making a VLP, said nucleic acid molecule comprising a contiguous sequence of nucleotides encoding i) a fusion polypeptide comprising a polypeptide of interest (POI) and at least a particle-associating portion of an L polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof, and ii) a small envelope (S) polypeptide of an avian hepadnavirus such as DHBV or a functional derivative thereof, wherein the POI is not a pre-S region of an avian hepadnavirus.
24. The nucleic acid molecule of claim 22 or 23 wherein the particle-associating portion of L comprises at least the S domain of L, or the S domain of L minus the TM1 domain, or a functional derivative thereof.
25. The nucleic acid molecule of claim 22 or 23 wherein the POI is located in the pre-S domain of L or at the amino terminal side of the S domain of L, or the S domain

- 62 -

minus the TM1 domain of L.

26. The nucleic acid molecule of claim 22 or 23 which encodes an L polypeptide comprising an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or comprises an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.
27. The nucleic acid molecule of claim 26 which encodes a particle associating portion of L polypeptide consisting essentially of amino acids 24 to 167 of SEQ ID NO: 9 or an amino acid sequence having at least 50% similarity to SEQ ID NO: 9.
28. The nucleic acid molecule of claim 22 or 23 wherein said L polypeptide or particle associating portion thereof is encoded by a sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or having at least about 50% similarity to SEQ ID NO: 6 or SEQ ID NO: 8 or a contiguous sequence of nucleotides capable of hybridizing to a complementary form of SEQ ID NO: 6 or SEQ ID NO: 8 under hybridisation conditions of medium stringency.
29. The nucleic acid molecule of claim 22 or 23 wherein the L polypeptide further comprises a signal sequence.
30. The nucleic acid molecule of claim 22 or 23 wherein the L polypeptide is a DHBV L polypeptide or functional derivative thereof.
31. A recombinant nucleic acid molecule for use in making a VLP, said nucleic acid molecule encoding a particle-associating portion of an L polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof and comprising one or more cloning sites suitable for accepting a nucleic acid molecule encoding a polypeptide of interest (POI), wherein said POI is expressed together with said L polypeptide and wherein the POI is not a pre-S region of an avian hepadnavirus.

- 63 -

32. A recombinant nucleic acid molecule for use in making a VLP, said nucleic acid molecule encoding at least a particle-associating portion of an L polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof, and ii) a small envelope (S) polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof and comprising one or more cloning sites suitable for accepting a nucleic acid molecule encoding a polypeptide of interest (POI), wherein said POI is expressed together with said L polypeptide and wherein the POI is not a pre-S region of an avian hepadnavirus.
33. The nucleic acid molecule of claim 31 or 32 wherein the particle-associating portion of L comprises at least the S domain of L, or the S domain of L minus the TM1 domain, or a functional derivative thereof.
34. The nucleic acid molecule of claim 31 or 32 wherein the POI is located in the pre-S domain of L or at the amino terminal side of the S domain of L, or the S domain minus the TM1 domain of L.
35. The nucleic acid molecule of claim 31 or 32 which encodes an L polypeptide comprising an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 or comprises an amino acid sequence having at least 50% similarity to SEQ ID NO: 7 or SEQ ID NO: 9.
36. The nucleic acid molecule of claim 35 which encodes a particle-associating portion of L polypeptide consisting essentially of amino acids 24 to 167 of SEQ ID NO: 9 or an amino acid sequence having at least 50% similarity to SEQ ID NO: 9.
37. The nucleic acid molecule of claim 31 or 32 wherein said L polypeptide or particle-associating portion thereof is encoded by a sequence of nucleotides substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8 or having at least about 50% similarity to SEQ ID NO: 6 or SEQ ID NO: 8 or a contiguous sequence of nucleotides capable of hybridizing to a complementary form of SEQ ID NO: 6 or SEQ ID NO:

- 64 -

8 under hybridisation conditions of medium stringency.

38. The nucleic acid molecule of claim 31 or 32 wherein the L polypeptide further comprises a signal sequence.
39. The nucleic acid molecule of claim 31 or 32 wherein the L polypeptide is a DHBV L polypeptide or functional derivative thereof.
40. An isolated and/or recombinant cell comprising the nucleic acid molecule of any one of claims 22 to 30 or expressing the polypeptide of any one of claims 12 to 21 or the VLP of any one of claims 1 to 11.
41. The cell according to claim 40 wherein said cell is a eukaryotic cell, preferably a yeast, avian or mammalian cell.
42. A method of delivering a POI to a subject or cell comprising expressing the POI in a VLP comprising L polypeptide from an avian hepadnavirus, such as DHBV, or a functional derivative thereof such that at least part of the POI is expressed on the surface of the VLP and administering the VLP to a subject or cell.
43. The method of claim 42 wherein the VLP is made in an *in vitro* expression system such as a yeast, avian or mammalian expression system.
44. The method of claim 42 wherein the VLP is made *in vivo* in the cells of a subject after administration of the nucleic acid molecule of any one of claims 22 to 30.
45. A method for making a recombinant VLP said method comprising:
 - i) cloning a nucleic acid molecule encoding a polypeptide of interest into an expression vector comprising a particle-associating portion of an L polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof;

- 65 -

- ii) introducing the recombinant expression vector of step i) into a suitable cell and maintaining same under conditions which allow protein expression and particle assembly with S polypeptide of an avian hepadnavirus, such as DHBV, or a functional derivative thereof; and
- iii) recovering said virus-like particles from said cells.

ABSTRACT

The present invention provides a virus-like particle (VLP) comprising i) a polypeptide comprising a polypeptide of interest (POI) and at least a particle-
5 associating portion of a large envelope (L) polypeptide of an avian hepadnavirus of a functional derivative or homolog thereof, and ii) a small enveloped (S) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof. By introducing one or more POIs into the L polypeptide, the POI is translocated along with L into a particle structure made up primarily of S polypeptide. The present invention
10 furthermore provides methods for producing a recombinant virus-like particle.

1/12






FIGURE 1

2/12



C. L-E2.465 chimera is translocated across the ER membrane

trypsin	-	+	+
NP-40	-	-	+

L-E2.465 —

S —

microsomes: protease protection assay

D. L-E2.465 chimera is assembled into particles

L-E2.465 —

S —

particles purified by sedimentation through 20% sucrose




FIGURE 2

3/12

DHBV full genome sequence (US D16 Acc. No. K01839)

1 catgctcatt tgaaagctta tgcaaaaatt aacgaggaat cactggatag ggctaggaga
 61 ttgctttggg ggcattacaa ctgtttactg tggggagaag ctcaagttac taactatatt
 121 tctcgtttgc gtacttgggt gtcaactcct gagaaatata gaggtagaga tgccccgacc
 181 attgaagcaa tctagtagacc aatccaggtg gctcagggag gcagaaaaac aactacgggt
 241 actagaaaac ctcgtggact cgaacctaga agaagaaaag taaaaccac agttgtctat
 301 gggagaagac gttcaaagtc ccgggaaagg agagccccta caccacaacg tgcgggctcc
 361 cctctcccac gtagttcgag cagccacat agatctccct cgcctaggaa ataaattacc
 421 tgctaggcat cacttaggta aattgtcagg actatatcaa atgaagggtt gtacttttaa
 481 cccagaatgg aaagtaccag atatttcgga tactcatttt aatttagatg tagttaatga
 541 gtgcccttcc cgaaattgga aatatttgac tccagccaaa ttctggccca agagcatttc
 601 ctactttcct gtccaggtag gggttaaacc aaagtatcct gacaatgtga tgcaacatga
 661 atcaatagta ggtaaatatt taaccaggct ctatgaagca ggaatccttt ataagcggat
 721 atctaaacat ttggtcacat ttaaagggtc gccttataat tgggaacagc aacacctgt
 781 caatcaacat cacatttatg atggggcaac atccagcaaa atcaatggac gtcagacgga
 841 tagaaggagg agaaatactg ttaaccaaac ttgccggaag gatgatccca aaagggactt
 901 tgacatggtc aggcaagttt ccaacactag atcacgtgtt agaccatgtg caaacaatgg
 961 aggagataaa caccctccag aatcagggag ctgggcctgc tggggcggga aggagagtag
 1021 gattatcaaa tccgactcct caagagattc ctacagccca gtggactccc gaggaagacc
 1081 aaaaagcacg cgaagctttt cgcgttatc aagaagaaag accaccggaa accaccacca
 1141 ttctccgctc ttcccctcct cagtgggaag tacaaccgga ggacgatcca ctctgggaa
 1201 atcagtctct cctcgagact catccgtat accagtcaga accagcgggt ccagtataa
 1261 aaactcccc ctgaagaag aaaatgtctg gtaccttcgg gggaatacta gctggcctaa
 1321 tccgattact ggtaagcttt ttctgttga taaaaattct agaaatactg aggaggctag
 1381 attggtgggt gatttctctc agttctccaa agggaaaaat gcaatgcgtt ttcaagata
 1441 ctggagccca aatctctcca cattacgtag gatcttgccc gtggggatgc ccaggatttc
 1501 ttggaccta tctcaggctt ttatcatct tctcttaat cctgctagta gcagcaggct
 1561 tgctgtatct gacggacaac gggcttacta ttttaggaaa gctccaatgg gctcgggtct
 1621 cagccctttt ctctccatc tcttactac tgccctcgga tccgaaatct ctgctcgtt
 1681 taacgtttgg actttcactt atatggatga ctctctctc tgccaccaa acgctcgtca
 1741 ccttaacgca attagccagc ctgtctgctc tttttacaa gagttaggaa taagaataa
 1801 ctttgacaaa accacgcctt ctccggtgaa tgaaataaga ttcctcggtt accagattga
 1861 tgaaaatttc atgaagattg aagaagcag atggaaagaa ttaaggactg taatcaagaa
 1921 aataaaagta ggagaatggt atgactggaa atgtattcaa agatttggtg ggcatttgaa
 1981 tttgttttg ccttttacta aaggaatat tgaaatgtta aaaccaatgt atgctgctat
 2041 tactaaccaa gtaaacttta gcttctctc atcctatagg actttgttat ataaactaac
 2101 aatgggtgtg tgtaaataa gaataaagcc aaagtcctct gtaccttgc cagtgtagc

FIGURE 3

4/12

2161 tacagatgct accccaacac atggcgcaat atcccatatc accggcgggga gcgcagtggt
2221 tgctttttca aaggtcagag atatacatgt tcaggaacta ttgatgtctt gtttagccaa
2281 gataatgatt aaaccacgtt gtctcttctc tgattcaact ttgtttgcc ataagcgta
2341 tcagacgta ccatggcatt ttgctatgtt ggccaaacaa ttgctcaaac cgatacaatt
2401 gtactttgtc ccgagcaaata ataactctgc tgacggccca tccaggcaca aacctctga
2461 ttggacggct ttccataca cccctctctc gaaagcaata tatattccac ataggctatg
2521 tggaaactaa gaattacacc cctctccttc ggagctgctt gccaaggat cttacgtct
2581 acattgctgt tgcgtgtgt gactgtacct ttggtatgta ccattgttta tgattctgc
2641 ttatatatgg atatcaatgc ttctagagcc ttagccaatg tgtatgatct accagatgat
2701 ttctttccaa aaatagatga tcttgtaga gatgctaaag acgctttaga gccttattgg
2761 aaatcagatt caataaagaa acatgtttg attgcaactc actttgtgga tctcattgaa
2821 gacttctggc agactacaca gggcatgcat gaaatagccg aatcattaag agctgttata
2881 cctcccacta ctactcctgt tccaccgggt tatcttattc agcacgagga agctgaagag
2941 atacctttgg gagatttatt taaacaccaa gaagaaagga tagtaagttt ccaacccgac
3001 tatccgatta cggctagaat t

FIGURE 3 Cont.

5/12

DHBV L sequence (US D16) (start L atg 801; start S atg 1284)

801/1 831/11
 atg ggg caa cat cca gca aaa tca atg gac gtc aga cgg ata gaa gga gaa gaa ata ctg
 M G Q P A K S M D V R R I E G G E I L
 861/21 891/31
 tta aac caa ctt gcc gga agg atg atc cca aaa ggg act ttg aca tgg tca ggc aag ttt
 L N Q Q L A G R M I P K G T L T W S G K F
 921/41 951/51
 cca aca cta gat cac gtg tta gac cat gtg caa aca atg gag gag ata aac acc ctc cag
 P T L D H V L D H V Q T M E I N T L Q
 981/61 1011/71
 aat cag gga gct tgg cct gct ggg ggc gga agg aga gta gga tta tca aat ccg act cct
 N Q G A W P A G A G R R V G L S N P T P
 1041/81 1071/91
 caa gag att cct cag ccc cag tgg act ccc gag gaa gac caa aaa gca cgc gaa gct ttt
 Q E I P Q P Q W T P E E D Q K A R E A F
 1101/101 1131/111
 cgc cgt tat caa gaa gaa aga cca ccg gaa acc acc acc att cct ccg tct tcc cct cct
 R R Y Q E R P P E T T T I P P S S P P
 1161/121 1191/131
 cag tgg aag cta caa ccc ggg gac gat cca ctc ctg gga aat cag tct ctc ctc gag act
 Q W K L Q P G D D P L L G N Q S L L E T
 1221/141 1251/151

FIGURE 4

6/12

cat ccg cta tac cag tca gaa cca gcg gtg cca gtg ata aaa act ccc ccc ttg aag aag
 H P L Y Q S E P A V P V I K T P P L K K
 1281/161
 aaa atg tct ggt acc ttc ggg gga ata cta gct ggc cta atc gga tta ctg gta agc ttt
 K M S G T F G I L A G L I G L L V S F
 1341/181
 ttc ttg ttg ata aaa att cta gaa ata ctg agg agg cta gat tgg tgg att tct ctc
 F L L I K I L E I L R R L D W W I S L
 1401/201
 agt tct cca aag gga aaa atg caa tgc gct ttc caa gat act gga gcc caa atc tct cca
 S S P K G K M Q C A F Q D T G A Q I S P
 1461/221
 cat tac gta gga tct tgc ccg tgg gga tgc cca gga ttt ctt tgg acc tat ctc agg ctt
 H Y V G S C P W G C P G F L W T Y L R L
 1521/241
 ttt atc atc ttc ctc tta atc ctg cta gta gca gca ggc ttg ctg tat ctg acg gac aac
 F I I F L L I L V A A G L L Y L T D N
 1581/261
 ggg tct act att tta gga aag ctc caa tgg gcg tcg gtc tca gcc ctt ttc tcc tcc atc
 G S T I L G K L Q W A S V S A L F S S I
 1641/281
 tct tca cta ctg ccc tcg gat ccg aaa tct ctc gtc gct tta acg ttt gga ctt tca ctt
 S S L L P S D P K S L V A L T F G L S L
 1701/301
 1731/311

FIGURE 4 Cont.

7/12

ata tgg atg act tcc tcc tct gcc acc caa acg ctc gtc acc tta acg caa tta gcc acg
 I W M T S S S A T Q T L V T L Q L A T
 1761/321 1791/331
 ctg tct gct ctt ttt tac aag agt tag
 L S A L F Y K S *

FIGURE 4 Cont.

8/12




FIGURE 5

9/12




FIGURE 5 cont.

10/12




A. SigL Δ TM1-E2.661 membrane fractionB. L Δ TM1-MSP2 membrane fraction


FIGURE 6

11/12

A. DL/S VLPs:sucrose step gradient profile



B. DLΔTM1-E2.465 VLPs: sucrose step gradient profile



C. DLΔTM1-HpreS VLPs: sucrose step gradient profile





FIGURE 7

12/12

rat sera:sequential bleeds
pre 1 2 4 5



preS reactivity

FIGURE 8

WO 2004/092387

PCT/AU2004/000511

- 1 -

SEQUENCE LISTING

<110> Hepgenics Pty Ltd

<120> Viral Vector

<130> 12437050/EJH

<150> AU 2003901876

<151> 2003-04-17

<160> 13

<170> PatentIn version 3.0

<210> 1

<211> 25

<212> DNA

<213> duck

<400> 1
gggcaacatc cagcaaaatc aatgg

25

<210> 2

<211> 30

<212> DNA

<213> human

<400> 2
gctgcggaat ggctaaaagg gcccccgacc

30

- 2 -

<210> 3

<211> 34

<212> DNA

<213> human

<400> 3

ccaacactag atcacgaaac ccacgtcacc gggg

34

<210> 4

<211> 34

<212> DNA

<213> human

<400> 4

ggttgtgatc tagtgctttg ggtgcagtgg cccc

34

<210> 5

<211> 3021

<212> DNA

<213> duck

<400> 5

catgctcatt tgaaagctta tgcaaaaatt aacgaggaat cactggatag ggctaggaga	60
ttgcttttggg ggcattacaa ctgtttactg tggggagaag ctcaagttac taactatatt	120
tctcgtttgc gtacttggtt gtcaactcct gagaaatata gaggtagaga tgccccgacc	180
attgaagcaa tcactagacc aatccagggtg gctcagggag gcagaaaaac aactacgggt	240
actagaaaac ctcgtaggact cgaacctaga agaagaaaag ttaaaaccac agttgtctat	300
gggagaagac gttcaaagtc ccgggaaagg agagccccta caccccaacg tgcgggctcc	360
cctctccac gtagttcgag cagccaccat agatctccct cgcctaggaa ataaattacc	420
tgctaggcat cacttaggta aattgtcagg actatatcaa atgaagggt gtacttttaa	480
cccagaatgg aaagtaccag atatttcgga tactcatttt aatttagatg tagttaatga	540

- 3 -

gtgcccttcc	cgaaattgga	aatatgtgac	tccagccaaa	ttctggccca	agagcatttc	600
ctactttcct	gtccaggtag	gggttaaacc	aaagtatcct	gacaatgtga	tgcaacatga	660
atcaatagta	ggtaaatatt	taaccagggt	ctatgaagca	ggaatccttt	ataagcggat	720
atctaaacat	ttggtcacat	ttaaagggtca	gccttataat	tggaacagc	aacaccttgt	780
caatcaacat	cacatttatg	atggggcaac	atccagcaaa	atcaatggac	gtcagacgga	840
tagaaggagg	agaaatactg	ttaaaccaac	ttgccggaag	gatgatccca	aaagggactt	900
tgacatggtc	aggcaagttt	ccaacactag	atcacgtgtt	agaccatgtg	caaacaatgg	960
aggagataaa	caccctccag	aatcaggagg	cttggcctgc	tggggcggga	aggagagtag	1020
gattatcaaa	tccgactcct	caagagattc	ctcagcccca	gtggactccc	gaggaagacc	1080
aaaaagcacg	cgaagctttt	cgccgttata	aagaagaaag	accaccggaa	accaccacca	1140
ttcctccgtc	ttccctcctc	cagtgggaagc	tacaaccggg	ggacgatcca	ctcctgggaa	1200
atcagtcctc	cctcgagact	catccgctat	accagtcaga	accagcgggtg	ccagtataaa	1260
aaactcccc	cttgaagaag	aaaatgtctg	gtaccttcgg	gggaatacta	gctggcctaa	1320
tcggattact	ggtaagcttt	ttcttggtga	taaaaattct	agaaatactg	aggaggctag	1380
attggtggtg	gatttctctc	agttctccaa	agggaaaaat	gcaatgcgct	ttccaagata	1440
ctggagccca	aatctctcca	cattacgtag	gatcttgccc	gtggggatgc	ccaggatttc	1500
tttggaacct	tctcaggctt	tttatcatct	tcctcttaat	cctgctagta	gcagcaggct	1560
tgctgtatct	gacggacaac	gggtctacta	ttttaggaaa	gctccaatgg	gcgtcggtct	1620
cagccctttt	ctcctccatc	tcttcactac	tgccctcgga	tccgaaatct	ctcgtcgctt	1680
taacgttttg	actttcactt	atatggatga	cttcctcctc	tgccacccaa	acgctcgta	1740
ccttaacgca	attagccacg	ctgtctgctc	ttttttacaa	gagttaggaa	taagaataaa	1800
ctttgacaaa	accacgcctt	ctccggtgaa	tgaaataaga	ttcctcggtt	accagattga	1860
tgaaaatttc	atgaagattg	aagaaagcag	atggaaagaa	ttaaggactg	taatcaagaa	1920
aataaaaagta	ggagaatggt	atgactggaa	atgtattcaa	agatttggtg	ggcatttgaa	1980
ttttgttttg	ccttttacta	aaggtaatat	tgaaatgtta	aaaccaatgt	atgctgctat	2040
tactaaccaa	gtaaacttta	gcttctcttc	atcctatagg	actttgttat	ataaactaac	2100
aatgggtgtg	tgtaaattaa	gaataaagcc	aaagtcctct	gtacctttgc	cacgtgtagc	2160
tacagatgct	acccaacac	atggcgcaat	atcccatatc	accggcggga	gcgcagtgtt	2220

- 4 -

```

tgctttttca aaggtcagag atatacatgt tcaggaacta ttgatgtctt gtttagccaa 2280
gataatgatt aaaccacgtt gtctcttata tgattcaact tttgtttgcc ataagcgta 2340
tcagacgtta ccatggcatt ttgctatgtt ggccaaacaa ttgctcaaac cgatacaatt 2400
gtactttgtc ccgagcaaata ataactctgc tgacggccca tccaggcaca aacctcctga 2460
ttggacgggt tttccataca cccctctctc gaaagcaata tatattccac ataggctatg 2520
tggaacttaa gaattacacc cctctccttc ggagctgctt gccaagggtat ctttacgtct 2580
acattgctgt tgtcgtgtgt gactgtacct ttggtatgta ccattgttta tgattcttgc 2640
ttatatatgg atatcaatgc ttctagagcc ttagccaatg tgtatgatct accagatgat 2700
ttctttccaa aaatagatga tcttgtaga gatgctaaag acgctttaga gccttattgg 2760
aaatcagatt caataaagaa acatgttttg attgcaactc actttgtgga tctcattgaa 2820
gacttctggc agactacaca gggcatgcat gaaatagccg aatcattaag agctgttata 2880
cctcccacta ctactcctgt tccaccgggt tatcttattc agcacgagga agctgaagag 2940
atacctttgg gagatttatt taaacaccaa gaagaaagga tagtaagttt ccaaccgcac 3000
tatccgatta cggctagaat t 3021

```

<210> 6

<211> 984

<212> DNA

<213> duck

<220>

<221> CDS

<222> (1)..(984)

<400> 6

```

atg ggg caa cat cca gca aaa tca atg gac gtc aga cgg ata gaa gga 48
Met Gly Gln His Pro Ala Lys Ser Met Asp Val Arg Arg Ile Glu Gly
1 5 10 15

gga gaa ata ctg tta aac caa ctt gcc gga agg atg atc cca aaa ggg 96
Gly Glu Ile Leu Leu Asn Gln Leu Ala Gly Arg Met Ile Pro Lys Gly
20 25 30

act ttg aca tgg tca ggc aag ttt cca aca cta gat cac gtg tta gac 144

```

- 5 -

Thr	Leu	Thr	Trp	Ser	Gly	Lys	Phe	Pro	Thr	Leu	Asp	His	Val	Leu	Asp	
	35						40					45				
cat	gtg	caa	aca	atg	gag	gag	ata	aac	acc	ctc	cag	aat	cag	gga	gct	192
His	Val	Gln	Thr	Met	Glu	Glu	Ile	Asn	Thr	Leu	Gln	Asn	Gln	Gly	Ala	
	50					55					60					
tgg	cct	gct	ggg	gcg	gga	agg	aga	gta	gga	tta	tca	aat	ccg	act	cct	240
Trp	Pro	Ala	Gly	Ala	Gly	Arg	Arg	Val	Gly	Leu	Ser	Asn	Pro	Thr	Pro	
	65				70					75					80	
caa	gag	att	cct	cag	ccc	cag	tgg	act	ccc	gag	gaa	gac	caa	aaa	gca	288
Gln	Glu	Ile	Pro	Gln	Pro	Gln	Trp	Thr	Pro	Glu	Glu	Asp	Gln	Lys	Ala	
				85					90					95		
cgc	gaa	gct	ttt	cgc	cgt	tat	caa	gaa	gaa	aga	cca	ccg	gaa	acc	acc	336
Arg	Glu	Ala	Phe	Arg	Arg	Tyr	Gln	Glu	Glu	Arg	Pro	Pro	Glu	Thr	Thr	
			100					105					110			
acc	att	cct	ccg	tct	tcc	cct	cct	cag	tgg	aag	cta	caa	ccc	ggg	gac	384
Thr	Ile	Pro	Pro	Ser	Ser	Pro	Pro	Gln	Trp	Lys	Leu	Gln	Pro	Gly	Asp	
		115					120					125				
gat	cca	ctc	ctg	gga	aat	cag	tct	ctc	ctc	gag	act	cat	ccg	cta	tac	432
Asp	Pro	Leu	Leu	Gly	Asn	Gln	Ser	Leu	Leu	Glu	Thr	His	Pro	Leu	Tyr	
	130					135					140					
cag	tca	gaa	cca	gcg	gtg	cca	gtg	ata	aaa	act	ccc	ccc	ttg	aag	aag	480
Gln	Ser	Glu	Pro	Ala	Val	Pro	Val	Ile	Lys	Thr	Pro	Pro	Leu	Lys	Lys	
	145				150					155					160	
aaa	atg	tct	ggt	acc	ttc	ggg	gga	ata	cta	gct	ggc	cta	atc	gga	tta	528
Lys	Met	Ser	Gly	Thr	Phe	Gly	Gly	Ile	Leu	Ala	Gly	Leu	Ile	Gly	Leu	
				165					170					175		
ctg	gta	agc	ttt	ttc	ttg	ttg	ata	aaa	att	cta	gaa	ata	ctg	agg	agg	576
Leu	Val	Ser	Phe	Phe	Leu	Leu	Ile	Lys	Ile	Leu	Glu	Ile	Leu	Arg	Arg	
			180					185					190			
cta	gat	tgg	tgg	tgg	att	tct	ctc	agt	tct	cca	aag	gga	aaa	atg	caa	624
Leu	Asp	Trp	Trp	Trp	Ile	Ser	Leu	Ser	Ser	Pro	Lys	Gly	Lys	Met	Gln	
		195					200					205				
tgc	gct	ttc	caa	gat	act	gga	gcc	caa	atc	tct	cca	cat	tac	gta	gga	672
Cys	Ala	Phe	Gln	Asp	Thr	Gly	Ala	Gln	Ile	Ser	Pro	His	Tyr	Val	Gly	
	210					215					220					
tct	tgc	ccg	tgg	gga	tgc	cca	gga	ttt	ctt	tgg	acc	tat	ctc	agg	ctt	720
Ser	Cys	Pro	Trp	Gly	Cys	Pro	Gly	Phe	Leu	Trp	Thr	Tyr	Leu	Arg	Leu	
	225				230					235					240	
ttt	atc	atc	ttc	ctc	tta	atc	ctg	cta	gta	gca	gca	ggc	ttg	ctg	tat	768
Phe	Ile	Ile	Phe	Leu	Leu	Ile	Leu	Leu	Val	Ala	Ala	Gly	Leu	Leu	Tyr	
				245					250					255		
ctg	acg	gac	aac	ggg	tct	act	att	tta	gga	aag	ctc	caa	tgg	gcg	tcg	816
Leu	Thr	Asp	Asn	Gly	Ser	Thr	Ile	Leu	Gly	Lys	Leu	Gln	Trp	Ala	Ser	

- 6 -

260	265	270	
gtc tca gcc ctt ttc tcc tcc atc tct tca cta ctg ccc tcg gat ccg			864
Val Ser Ala Leu Phe Ser Ser Ile Ser Ser Leu Leu Pro Ser Asp Pro			
275	280	285	
aaa tct ctc gtc gct tta acg ttt gga ctt tca ctt ata tgg atg act			912
Lys Ser Leu Val Ala Leu Thr Phe Gly Leu Ser Leu Ile Trp Met Thr			
290	295	300	
tcc tcc tct gcc acc caa acg ctc gtc acc tta acg caa tta gcc acg			960
Ser Ser Ser Ala Thr Gln Thr Leu Val Thr Leu Thr Gln Leu Ala Thr			
305	310	315	320
ctg tct gct ctt ttt tac aag agt			984
Leu Ser Ala Leu Phe Tyr Lys Ser			
325			

<210> 7

<211> 328

<212> PRT

<213> duck

<400> 7

Met Gly Gln His Pro Ala Lys Ser Met Asp Val Arg Arg Ile Glu Gly	
1 5 10 15	
Gly Glu Ile Leu Leu Asn Gln Leu Ala Gly Arg Met Ile Pro Lys Gly	
20 25 30	
Thr Leu Thr Trp Ser Gly Lys Phe Pro Thr Leu Asp His Val Leu Asp	
35 40 45	
His Val Gln Thr Met Glu Glu Ile Asn Thr Leu Gln Asn Gln Gly Ala	
50 55 60	
Trp Pro Ala Gly Ala Gly Arg Arg Val Gly Leu Ser Asn Pro Thr Pro	
65 70 75 80	
Gln Glu Ile Pro Gln Pro Gln Trp Thr Pro Glu Glu Asp Gln Lys Ala	
85 90 95	
Arg Glu Ala Phe Arg Arg Tyr Gln Glu Glu Arg Pro Pro Glu Thr Thr	
100 105 110	

- 7 -

Thr Ile Pro Pro Ser Ser Pro Pro Gln Trp Lys Leu Gln Pro Gly Asp
 115 120 125

Asp Pro Leu Leu Gly Asn Gln Ser Leu Leu Glu Thr His Pro Leu Tyr
 130 135 140

Gln Ser Glu Pro Ala Val Pro Val Ile Lys Thr Pro Pro Leu Lys Lys
 145 150 155 160

Lys Met Ser Gly Thr Phe Gly Gly Ile Leu Ala Gly Leu Ile Gly Leu
 165 170 175

Leu Val Ser Phe Phe Leu Leu Ile Lys Ile Leu Glu Ile Leu Arg Arg
 180 185 190

Leu Asp Trp Trp Trp Ile Ser Leu Ser Ser Pro Lys Gly Lys Met Gln
 195 200 205

Cys Ala Phe Gln Asp Thr Gly Ala Gln Ile Ser Pro His Tyr Val Gly
 210 215 220

Ser Cys Pro Trp Gly Cys Pro Gly Phe Leu Trp Thr Tyr Leu Arg Leu
 225 230 235 240

Phe Ile Ile Phe Leu Leu Ile Leu Leu Val Ala Ala Gly Leu Leu Tyr
 245 250 255

Leu Thr Asp Asn Gly Ser Thr Ile Leu Gly Lys Leu Gln Trp Ala Ser
 260 265 270

Val Ser Ala Leu Phe Ser Ser Ile Ser Ser Leu Leu Pro Ser Asp Pro
 275 280 285

Lys Ser Leu Val Ala Leu Thr Phe Gly Leu Ser Leu Ile Trp Met Thr
 290 295 300

Ser Ser Ser Ala Thr Gln Thr Leu Val Thr Leu Thr Gln Leu Ala Thr
 305 310 315 320

Leu Ser Ala Leu Phe Tyr Lys Ser
 325

- 8 -

<210> 8

<211> 501

<212> DNA

<213> duck

<220>

<221> CDS

<222> (1)..(501)

```

<400> 8
atg tct ggt acc ttc ggg gga ata cta gct ggc cta atc gga tta ctg      48
Met Ser Gly Thr Phe Gly Gly Ile Leu Ala Gly Leu Ile Gly Leu Leu
1          5          10          15

gta agc ttt ttc ttg ttg ata aaa att cta gaa ata ctg agg agg cta      96
Val Ser Phe Phe Leu Leu Ile Lys Ile Leu Glu Ile Leu Arg Arg Leu
          20          25          30

gat tgg tgg tgg att tct ctc agt tct cca aag gga aaa atg caa tgc      144
Asp Trp Trp Trp Ile Ser Leu Ser Ser Pro Lys Gly Lys Met Gln Cys
          35          40          45

gct ttc caa gat act gga gcc caa atc tct cca cat tac gta gga tct      192
Ala Phe Gln Asp Thr Gly Ala Gln Ile Ser Pro His Tyr Val Gly Ser
          50          55          60

tgc ccg tgg gga tgc cca gga ttt ctt tgg acc tat ctc agg ctt ttt      240
Cys Pro Trp Gly Cys Pro Gly Phe Leu Trp Thr Tyr Leu Arg Leu Phe
          65          70          75          80

atc atc ttc ctc tta atc ctg cta gta gca gca ggc ttg ctg tat ctg      288
Ile Ile Phe Leu Leu Ile Leu Leu Val Ala Ala Gly Leu Leu Tyr Leu
          85          90          95

acg gac aac ggg tct act att tta gga aag ctc caa tgg gcg tcg gtc      336
Thr Asp Asn Gly Ser Thr Ile Leu Gly Lys Leu Gln Trp Ala Ser Val
          100          105          110

tca gcc ctt ttc tcc tcc atc tct tca cta ctg ccc tcg gat ccg aaa      384
Ser Ala Leu Phe Ser Ser Ile Ser Ser Leu Leu Pro Ser Asp Pro Lys
          115          120          125

tct ctc gtc gct tta acg ttt gga ctt tca ctt ata tgg atg act tcc      432
Ser Leu Val Ala Leu Thr Phe Gly Leu Ser Leu Ile Trp Met Thr Ser
          130          135          140

tcc tct gcc acc caa acg ctc gtc acc tta acg caa tta gcc acg ctg      480

```

- 9 -

Ser Ser Ala Thr Gln Thr Leu Val Thr Leu Thr Gln Leu Ala Thr Leu
 145 150 155 160

tct gct ctt ttt tac aag agt
 Ser Ala Leu Phe Tyr Lys Ser
 165

501

<210> 9

<211> 167

<212> PRT

<213> duck

<400> 9

Met Ser Gly Thr Phe Gly Gly Ile Leu Ala Gly Leu Ile Gly Leu Leu
 1 5 10 15

Val Ser Phe Phe Leu Leu Ile Lys Ile Leu Glu Ile Leu Arg Arg Leu
 20 25 30

Asp Trp Trp Trp Ile Ser Leu Ser Ser Pro Lys Gly Lys Met Gln Cys
 35 40 45

Ala Phe Gln Asp Thr Gly Ala Gln Ile Ser Pro His Tyr Val Gly Ser
 50 55 60

Cys Pro Trp Gly Cys Pro Gly Phe Leu Trp Thr Tyr Leu Arg Leu Phe
 65 70 75 80

Ile Ile Phe Leu Leu Ile Leu Leu Val Ala Ala Gly Leu Leu Tyr Leu
 85 90 95

Thr Asp Asn Gly Ser Thr Ile Leu Gly Lys Leu Gln Trp Ala Ser Val
 100 105 110

Ser Ala Leu Phe Ser Ser Ile Ser Ser Leu Leu Pro Ser Asp Pro Lys
 115 120 125

Ser Leu Val Ala Leu Thr Phe Gly Leu Ser Leu Ile Trp Met Thr Ser
 130 135 140

Ser Ser Ala Thr Gln Thr Leu Val Thr Leu Thr Gln Leu Ala Thr Leu

- 10 -

145

150

155

160

Ser Ala Leu Phe Tyr Lys Ser
165

<210> 10

<211> 483

<212> DNA

<213> duck

<220>

<221> CDS

<222> (1)..(483)

<400> 10

atg ggg caa cat cca gca aaa tca atg gac gtc aga cgg ata gaa gga 48
Met Gly Gln His Pro Ala Lys Ser Met Asp Val Arg Arg Ile Glu Gly
1 5 10 15

gga gaa ata ctg tta aac caa ctt gcc gga agg atg atc cca aaa ggg 96
Gly Glu Ile Leu Leu Asn Gln Leu Ala Gly Arg Met Ile Pro Lys Gly
20 25 30

act ttg aca tgg tca ggc aag ttt cca aca cta gat cac gtg tta gac 144
Thr Leu Thr Trp Ser Gly Lys Phe Pro Thr Leu Asp His Val Leu Asp
35 40 45

cat gtg caa aca atg gag gag ata aac acc ctc cag aat cag gga gct 192
His Val Gln Thr Met Glu Glu Ile Asn Thr Leu Gln Asn Gln Gly Ala
50 55 60

tgg cct gct ggg gcg gga agg aga gta gga tta tca aat ccg act cct 240
Trp Pro Ala Gly Ala Gly Arg Arg Val Gly Leu Ser Asn Pro Thr Pro
65 70 75 80

caa gag att cct cag ccc cag tgg act ccc gag gaa gac caa aaa gca 288
Gln Glu Ile Pro Gln Pro Gln Trp Thr Pro Glu Glu Asp Gln Lys Ala
85 90 95

cgc gaa gct ttt cgc cgt tat caa gaa gaa aga cca ccg gaa acc acc 336
Arg Glu Ala Phe Arg Arg Tyr Gln Glu Glu Arg Pro Pro Glu Thr Thr
100 105 110

acc att cct ccg tct tcc cct cct cag tgg aag cta caa ccc ggg gac 384
Thr Ile Pro Pro Ser Ser Pro Pro Gln Trp Lys Leu Gln Pro Gly Asp
115 120 125

- 11 -

gat cca ctc ctg gga aat cag tct ctc ctc gag act cat ccg cta tac 432
 Asp Pro Leu Leu Gly Asn Gln Ser Leu Leu Glu Thr His Pro Leu Tyr
 130 135 140

cag tca gaa cca gcg gtg cca gtg ata aaa act ccc ccc ttg aag aag 480
 Gln Ser Glu Pro Ala Val Pro Val Ile Lys Thr Pro Pro Leu Lys Lys
 145 150 155 160

aaa 483
 Lys

<210> 11

<211> 161

<212> PRT

<213> duck

<400> 11

Met Gly Gln His Pro Ala Lys Ser Met Asp Val Arg Arg Ile Glu Gly
 1 5 10 15

Gly Glu Ile Leu Leu Asn Gln Leu Ala Gly Arg Met Ile Pro Lys Gly
 20 25 30

Thr Leu Thr Trp Ser Gly Lys Phe Pro Thr Leu Asp His Val Leu Asp
 35 40 45

His Val Gln Thr Met Glu Glu Ile Asn Thr Leu Gln Asn Gln Gly Ala
 50 55 60

Trp Pro Ala Gly Ala Gly Arg Arg Val Gly Leu Ser Asn Pro Thr Pro
 65 70 75 80

Gln Glu Ile Pro Gln Pro Gln Trp Thr Pro Glu Glu Asp Gln Lys Ala
 85 90 95

Arg Glu Ala Phe Arg Arg Tyr Gln Glu Glu Arg Pro Pro Glu Thr Thr
 100 105 110

Thr Ile Pro Pro Ser Ser Pro Pro Gln Trp Lys Leu Gln Pro Gly Asp
 115 120 125

- 12 -

Asp Pro Leu Leu Gly Asn Gln Ser Leu Leu Glu Thr His Pro Leu Tyr
 130 135 140

Gln Ser Glu Pro Ala Val Pro Val Ile Lys Thr Pro Pro Leu Lys Lys
 145 150 155 160

Lys

<210> 12

<211> 501

<212> DNA

<213> duck

<220>

<221> CDS

<222> (1)..(501)

<400> 12

atg tct ggt acc ttc ggg gga ata cta gct ggc cta atc gga tta ctg 48
 Met Ser Gly Thr Phe Gly Gly Ile Leu Ala Gly Leu Ile Gly Leu Leu
 1 5 10 15

gta agc ttt ttc ttg ttg ata aaa att cta gaa ata ctg agg agg cta 96
 Val Ser Phe Phe Leu Leu Ile Lys Ile Leu Glu Ile Leu Arg Arg Leu
 20 25 30

gat tgg tgg tgg att tct ctc agt tct cca aag gga aaa atg caa tgc 144
 Asp Trp Trp Trp Ile Ser Leu Ser Ser Pro Lys Gly Lys Met Gln Cys
 35 40 45

gct ttc caa gat act gga gcc caa atc tct cca cat tac gta gga tct 192
 Ala Phe Gln Asp Thr Gly Ala Gln Ile Ser Pro His Tyr Val Gly Ser
 50 55 60

tgc ccg tgg gga tgc cca gga ttt ctt tgg acc tat ctc agg ctt ttt 240
 Cys Pro Trp Gly Cys Pro Gly Phe Leu Trp Thr Tyr Leu Arg Leu Phe
 65 70 75 80

atc atc ttc ctc tta atc ctg cta gta gca gca ggc ttg ctg tat ctg 288
 Ile Ile Phe Leu Leu Ile Leu Leu Val Ala Ala Gly Leu Leu Tyr Leu
 85 90 95

acg gac aac ggg tct act att tta gga aag ctc caa tgg gcg tcg gtc 336

- 13 -

Thr	Asp	Asn	Gly	Ser	Thr	Ile	Leu	Gly	Lys	Leu	Gln	Trp	Ala	Ser	Val		
			100					105					110				
tca	gcc	ctt	ttc	tcc	tcc	atc	tct	tca	cta	ctg	ccc	tcg	gat	ccg	aaa		384
Ser	Ala	Leu	Phe	Ser	Ser	Ile	Ser	Ser	Leu	Leu	Pro	Ser	Asp	Pro	Lys		
		115					120				125						
tct	ctc	gtc	gct	tta	acg	ttt	gga	ctt	tca	ctt	ata	tgg	atg	act	tcc		432
Ser	Leu	Val	Ala	Leu	Thr	Phe	Gly	Leu	Ser	Leu	Ile	Trp	Met	Thr	Ser		
		130				135					140						
tcc	tct	gcc	acc	caa	acg	ctc	gtc	acc	tta	acg	caa	tta	gcc	acg	ctg		480
Ser	Ser	Ala	Thr	Gln	Thr	Leu	Val	Thr	Leu	Thr	Gln	Leu	Ala	Thr	Leu		
145					150				155						160		
tct	gct	ctt	ttt	tac	aag	agt											501
Ser	Ala	Leu	Phe	Tyr	Lys	Ser											
				165													

<210> 13

<211> 167

<212> PRT

<213> duck

<400> 13

Met	Ser	Gly	Thr	Phe	Gly	Gly	Ile	Leu	Ala	Gly	Leu	Ile	Gly	Leu	Leu		
1				5					10					15			

Val	Ser	Phe	Phe	Leu	Leu	Ile	Lys	Ile	Leu	Glu	Ile	Leu	Arg	Arg	Leu		
		20					25						30				

Asp	Trp	Trp	Trp	Ile	Ser	Leu	Ser	Ser	Pro	Lys	Gly	Lys	Met	Gln	Cys		
		35					40					45					

Ala	Phe	Gln	Asp	Thr	Gly	Ala	Gln	Ile	Ser	Pro	His	Tyr	Val	Gly	Ser		
	50					55					60						

Cys	Pro	Trp	Gly	Cys	Pro	Gly	Phe	Leu	Trp	Thr	Tyr	Leu	Arg	Leu	Phe		
65					70					75					80		

Ile	Ile	Phe	Leu	Leu	Ile	Leu	Leu	Val	Ala	Ala	Gly	Leu	Leu	Tyr	Leu		
			85					90						95			

Thr	Asp	Asn	Gly	Ser	Thr	Ile	Leu	Gly	Lys	Leu	Gln	Trp	Ala	Ser	Val		
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	--	--

- 14 -

100	105	110
Ser Ala Leu Phe Ser Ser Ile Ser Ser Leu Leu Pro Ser Asp Pro Lys		
115	120	125
Ser Leu Val Ala Leu Thr Phe Gly Leu Ser Leu Ile Trp Met Thr Ser		
130	135	140
Ser Ser Ala Thr Gln Thr Leu Val Thr Leu Thr Gln Leu Ala Thr Leu		
145	150	155 160
Ser Ala Leu Phe Tyr Lys Ser		
165		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/000511

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁷ : C12N 15/62, 7/01, 15/63 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) SBE BELOW Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SBE BELOW Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS, CA, MEDLINE:L or large envelope protein, pre S, virus, vlp, fusion, chimeric, chimaeric, hepatitis, hepadnavirus, recombinant fusion proteins, envelope proteins		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Ishikawa T and Ganem D (1995) "The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses" Proc Natl Acad Sci USA 92, 6259-63 See in particular figure 4	1-42, 46
X	Kuroda S et al (1992) "Hepatitis B virus envelope L protein particles" J Biol Chem 267(3), 1953-61 See whole document	1-5, 13-15, 23-25, 32-34, 41, 42, 46
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 21 May 2004		Date of mailing of the international search report 27 MAY 2004
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer TERRY MOORE Telephone No : (02) 6283 2632